

STIC-ILL

DP91.A2

From: Gambel, Phillip
Sent: Thursday, November 02, 2000 4:34 PM
To: STIC-ILL
Subject: 09/358116

stic

please provide the following references to

phillip gambel
art unit 1644
308-3997

1644 maiblox 9E12

1. sackstein et al. blood 89 (8) : 2773 -2781 (1997)
2. sackstein et al. acta haemtologica (basel) 97 (1-2) : 22 - 28 (1997)

3. sackstein et al. blood 84 (10) : 3299 - 3306 (1994)

PLEASE COPY FRONT COVER SO I CAN DETERMINE DATE OF JOURNAL THANX

4. watson et al. adv. vasc. biol. 3 : 179 - 193 (1997)
5. imai et al. immuno. front. 4 (1) : 25 - 31 (1994)
6. rosen et al. res. immunol. 144 (9) : 699 - 703 (1993)
7. rosen et al. histochemistry 100 (3) : 185 -191 (1993)

thanx

STIC-ILL

mic
RB/45, A2B56

From: Gambel, Phillip
Sent: Thursday, November 02, 2000 4:34 PM
To: STIC-ILL
Subject: 09/358116

stic

please provide the following references to

phillip gambel
art unit 1644
308-3997

1644 maiblox 9E12

1. sackstein et al. blood 89 (8) : 2773 -2781 (1997)
2. sackstein et al. acta haemtologica (basel) 97 (1-2) : 22 - 28 (1997)

3. sackstein et al. blood 84 (10) : 3299 - 3306 (1994)
PLEASE COPY FRONT COVER SO I CAN DETERMINE DATE OF JOURNAL THANX

4. watson et al. adv. vasc. biol. 3 : 179 - 193 (1997)
5. imai et al. immuno. front. 4 (1) : 25 - 31 (1994)
6. rosen et al. res. immunol. 144 (9) : 699 - 703 (1993)
7. rosen et al. histochemistry 100 (3) : 185 -191 (1993)

thanx

STIC-ILL

ADONIS
QH611,243

From: Gambel, Phillip
Sent: Thursday, November 02, 2000 4:34 PM
To: STIC-ILL
Subject: 09/358116

stic

please provide the following references to

phillip gambel
art unit 1644
308-3997

25 -

1644 maiblox 9E12

1. sackstein et al. blood 89 (8) : 2773 -2781 (1997)
2. sackstein et al. acta haemtologica (basel) 97 (1-2) : 22 - 28 (1997)
3. sackstein et al. blood 84 (10) : 3299 - 3306 (1994)
PLEASE COPY FRONT COVER SO I CAN DETERMINE DATE OF JOURNAL THANX
4. watson et al. adv. vasc. biol. 3 : 179 - 193 (1997)
5. imai et al. immuno. front. 4 (1) : 25 - 31 (1994)
6. rosen et al. res. immunol. 144 (9) : 699 - 703 (1993)
7. rosen et al. histochemistry 100 (3) : 185 -191 (1993)

thanx

ADONIS - Electronic Journal Services

Requested by

Adonis

Article title	L-Selectin and its biological ligands
Article identifier	0301556493000871
Authors	Rosen_S_D
Journal title	Histochemistry
ISSN	0301-5564
Publisher	Springer
Year of publication	1993
Volume	100
Issue	3
Supplement	0
Page range	185-191
Number of pages	7
User name	Adonis
Cost centre	Development
PCC	\$25.00
Date and time	Thursday, November 02, 2000 5:03:56 PM

Copyright © 1991-1999 ADONIS and/or licensors.

The use of this system and its contents is restricted to the terms and conditions laid down in the Journal Delivery and User Agreement. Whilst the information contained on each CD-ROM has been obtained from sources believed to be reliable, no liability shall attach to ADONIS or the publisher in respect of any of its contents or in respect of any use of the system.

WEST[Generate Collection](#)**Search Results - Record(s) 1 through 4 of 4 returned.**☐ 1. Document ID: US 6117680 A

L4: Entry 1 of 4

File: USPT

Sep 12, 2000

US-PAT-NO: 6117680

DOCUMENT-IDENTIFIER: US 6117680 A

TITLE: Compositions and methods for regulation of transcription

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Natesan; Sridaran	Chestnut Hill	MA	N/A	N/A
Gilman; Michael Z.	Newton	MA	N/A	N/A

US-CL-CURRENT: 435/455; 435/235.1, 435/320.1, 435/325, 435/456, 536/23.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 2. Document ID: US 6001988 A

L4: Entry 2 of 4

File: USPT

Dec 14, 1999

US-PAT-NO: 6001988

DOCUMENT-IDENTIFIER: US 6001988 A

TITLE: High affinity nucleic acid ligands to lectins

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Parma; David H.	Boulder	CO	N/A	N/A
Hicke; Brian J.	Boulder	CO	N/A	N/A
Bridonneau; Philippe	Boulder	CO	N/A	N/A
Gold; Larry	Boulder	CO	N/A	N/A

US-CL-CURRENT: 536/24.3; 435/6, 435/91.2, 536/22.1, 536/25.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 3. Document ID: US 5780228 A

L4: Entry 3 of 4

File: USPT

Jul 14, 1998

US-PAT-NO: 5780228

DOCUMENT-IDENTIFIER: US 5780228 A

TITLE: High affinity nucleic acid ligands to lectins

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Parma; David H.	Boulder	CO	N/A	N/A
Hicke; Brian	Boulder	CO	N/A	N/A
Bridonneau; Philippe	Boulder	CO	N/A	N/A
Gold; Larry	Boulder	CO	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.1, 536/22.1, 536/23.1, 536/24.33, 536/25.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 4. Document ID: US 5766853 A

L4: Entry 4 of 4

File: USPT

Jun 16, 1998

US-PAT-NO: 5766853

DOCUMENT-IDENTIFIER: US 5766853 A

TITLE: Method for identification of high affinity nucleic acid ligands to selectins

DATE-ISSUED: June 16, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Parma; David H.	Boulder	CO	N/A	N/A
Hicke; Brian James	Boulder	CO	N/A	N/A
Gold; Larry	Boulder	CO	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.1, 536/22.1, 536/23.1, 536/24.33, 536/25.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

[Generate Collection](#)

Term	Documents
L-SELECTIN.USPT.	299
L-SELECTINS.USPT.	24
LIGAND\$	0
LIGAND.USPT.	28117
LIGANDA.USPT.	3
LIGANDABLE.USPT.	1
LIGANDACTIVATED.USPT.	2
LIGANDAL.USPT.	1
LIGANDAMIDOSERINE.USPT.	1
LIGANDAND.USPT.	2
('L-SELECTIN' SAME LIGAND\$ SAME (HEMOPOIETIC OR HEMATOPOIETIC OR STEM OR PLURIPOTENT\$)).USPT.	4

[There are more results than shown above. Click here to view the entire set.](#)

Display

10

Documents, starting with Document:

4

Display Format:

CIT

Change Format

n plc

Set	Items	Description
---	-----	-----

? b 410

>>>'IALOG' not recognized as set or accession number
? set hi ;set hi

02nov00	16:18:08	User208760	Session D1703.3
	\$0.00	0.151	DialUnits File410
\$0.00	Estimated cost File410		
\$0.05	TYMNET		
\$0.05	Estimated cost this search		
\$0.05	Estimated total session cost 0.151 DialUnits		

File 410:Chronolog(R) 1981-2000 Sep/Oct
(c) 2000 The Dialog Corporation plc

Set	Items	Description
---	-----	-----

?

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 652,653,654

02nov00	16:18:17	User208760	Session D1703.4
	\$0.00	0.059	DialUnits File410
\$0.00	Estimated cost File410		
\$0.01	TYMNET		
\$0.01	Estimated cost this search		
\$0.06	Estimated total session cost 0.209 DialUnits		

SYSTEM:OS - DIALOG OneSearch

File 652:US Patents Fulltext 1971-1979

(c) format only 2000 The Dialog Corp.

*File 652: Reassignment data current through 7/25/2000 recordings.
Due to recent processing problems, the SORT command is not working.

File 653:US Pat.Fulltext 1980-1989

(c) format only 2000 The Dialog Corp.

*File 653: Reassignment data current through 7/25/2000 recordings.
Due to recent processing problems, the SORT command is not working.

File 654:US Pat.Full. 1990-2000/Oct 31

(c) format only 2000 The Dialog Corp.

*File 654: Reassignment data current through 7/25/2000 recordings.
Due to recent processing problems, the SORT command is not working.

Set	Items	Description
---	-----	-----

? s l(w)selectin(w)ligand?

1118908	L
793	SELECTIN
35359	LIGAND?
S1	37 L(W)SELECTIN(W)LIGAND?

? t s1/3/all

1/3/1 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03205532

Utility

.BETA.-1-6-N-ACETYLGLUCOSAMINYLTRANSFERASE THAT FORMS CORE 2, CORE 4 AND I BRANCHES

PATENT NO.: 6,136,580

ISSUED: October 24, 2000 (20001024)

INVENTOR(s): Fukuda, Minoru, San Diego, CA (California), US (United States of America)
Yeh, Jiunn-Chern, La Jolla, CA (California), US (United States of America)

ASSIGNEE(s): The Burnham Institute, (A U.S. Company or Corporation), La Jolla, CA (California), US (United States of America)
[Assignee Code(s): 41683]

APPL. NO.: 9-233,506

FILED: January 19, 1999 (19990119)

This invention was made in part with Government support under Grant Nos. CA33000 and CA71932. The Government may have certain rights in this invention.

FULL TEXT: 1718 lines

1/3/2 (Item 2 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03137524

Utility

NUCLEIC ACIDS ENCODING NL-3

PATENT NO.: 6,074,873

ISSUED: June 13, 2000 (20000613)

INVENTOR(s): Fong, Sherman, Alameda, CA (California), US (United States of America)
Ferrara, Napoleone, San Francisco, CA (California), US (United States of America)
Goddard, Audrey, San Francisco, CA (California), US (United States of America)
Godowski, Paul J., Burlingame, CA (California), US (United States of America)
Gurney, Austin L., Belmont, CA (California), US (United States of America)
Hillan, Kenneth, San Francisco, CA (California), US (United States of America)
Williams, P. Mickey, Half Moon Bay, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 9-143,068

FILED: August 28, 1998 (19980828)

This is a continuation-in-part of co-pending application(s) Ser. No. 08-934,494 filed on Sep. 19, 1997, to which application(s) priority is claimed under 35 USC selection 120.

FULL TEXT: 3327 lines

1/3/3 (Item 3 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03117603

Utility
TIE LIGAND HOMOLOGUES

PATENT NO.: 6,057,435
ISSUED: May 02, 2000 (20000502)
INVENTOR(s): Godowski, Paul J., Burlingame, CA (California), US (United States of America)
Gurney, Austin L., Belmont, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), So. San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-960,507
FILED: October 29, 1997 (19971029)

This is a continuation-in-part of co-pending U.S. application Ser. No. 08-933,821, filed Sep. 19, 1997.

FULL TEXT: 3316 lines

1/3/4 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03087890

Utility
TIE LIGAND HOMOLOGUES

[Nucleotide sequence of receptor tyrosine kinase containing immunoglobulin and epidermal growth factor homology domains; for diagnosis of tumors; targeted antitumor agents and angiogenesis inhibitors; antiischemic agents]

PATENT NO.: 6,030,831
ISSUED: February 29, 2000 (20000229)
INVENTOR(s): Godowski, Paul J., Pacifica, CA (California), US (United States of America)
Gurney, Austin L., Belmont, CA (California), US (United States of America)
ASSIGNEE(s): Genetech, Inc , (A U.S. Company or Corporation), So. San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-934,494
FILED: September 19, 1997 (19970919)
FULL TEXT: 2509 lines

1/3/5 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03084806

Utility
HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

[Isolated and purified polypeptide of given amino acid sequence which binds a ligand of trkC(receptor tyrosine kinases) or trkB and is homogeneous]

PATENT NO.: 6,027,927
ISSUED: February 22, 2000 (20000222)
INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Shelton, David L., Pacifica, CA (California), US (United States of America)
Urfer, Roman, Pacifica, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San

Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-942,562
FILED: October 01, 1997 (19971001)

This is a continuation of application Ser. No. 08-444,597 filed on May 19, 1995, now abandoned, which is a continuation-in-part of Ser. No. 08-286,846 filed Aug. 5, 1994, U.S. Pat. No. 5,877,016 which is a continuation of Ser. No. 08-215,139 filed Mar. 18, 1994, now abandoned which applications are incorporated herein by reference and to which application priority is claimed under 35 USC selection 120.

FULL TEXT: 4470 lines

1/3/6 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03081637

Utility

HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

[Amino acid sequences of receptor tyrosine kinase C ligand-binding polypeptide; for immunoadhesins; diagnosis of nervous system disorders; anticarcinogenic agents; analgesics]

PATENT NO.: 6,025,166
ISSUED: February 15, 2000 (20000215)
INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Shelton, David L., Pacifica, CA (California), US (United States of America)
Urfer, Roman, Pacifica, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-444,622
FILED: May 19, 1995 (19950519)

This is a continuation of application Ser. No. 08-286,846, filed on Aug. 5, 1994, now U.S. Pat. No. 5,877,016, which is a continuation-in-part of application Ser. No. 08-215,139, filed Mar. 18, 1994, now abandoned, which applications are incorporated herein by reference and to which applications priority is claimed under 35 U.S.C. selection 120.

FULL TEXT: 4560 lines

1/3/7 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03055283

Utility

HIGH AFFINITY NUCLEIC ACID LIGANDS TO LECTINS

[Purified, isolated synthetic nucleic acid to wheat germ agglutinin, serum mannose binding protein, or a selectin; antiinflammatory agents; antiarthritic agents; antimetastasis agents; diagnostic and prophylactic agents]

PATENT NO.: 6,001,988
ISSUED: December 14, 1999 (19991214)
INVENTOR(s): Parma, David H., Boulder, CO (Colorado), US (United States of America)
Hicke, Brian J., Boulder, CO (Colorado), US (United States of America)

Bridonneau, Philippe, Boulder, CO (Colorado), US (United States of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 8-472,256
FILED: June 07, 1995 (19950607)

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application Ser. No. 07-714,131, filed Jun. 10, 1991, entitled Nucleic Acid Ligands, now U.S. Pat. No. 5,475,096, which is a Continuation-in Part of U.S. patent application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled Systematic Evolution of Ligands by Exponential Enrichment, now abandoned. This application is also a continuation-in-part of U.S. patent application Ser. No. 07-964,624, filed Oct. 21, 1992, entitled Methods of Producing Nucleic Acid Ligands now U.S. Pat. No. 5,496,938.

FULL TEXT: 5144 lines

1/3/8 (Item 8 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03042366

Utility
HOMOGENEOUS DETECTION OF A TARGET THROUGH NUCLEIC ACID LIGAND-LIGAND BEACON INTERACTION
[Measuring fluorescent emission]

PATENT NO.: 5,989,823
ISSUED: November 23, 1999 (19991123)
INVENTOR(s): Jayasena, Sumedha, Boulder, CO (Colorado), US (United States of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 9-157,206
FILED: September 18, 1998 (19980918)
FULL TEXT: 1445 lines

1/3/9 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037991

Utility
INHIBITION OF SELECTIN BINDING
[Composition for inhibiting binding between a first cell having a P- or L-selectin and a second cell having a ligand for the selectin, comprising a sheet of lipids]

PATENT NO.: 5,985,852
ISSUED: November 16, 1999 (19991116)
INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)
Spevak, Wayne R., Albany, CA (California), US (United States of America)
Dasgupta, Falguni, New Delhi, IN (India)

Bertozzi, Caroline, Albany, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 9-250,999
FILED: February 16, 1999 (19990216)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of pending U.S. patent application Ser. No. 08-807,428, filed Feb. 28, 1997, which claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, both of which are hereby incorporated herein by reference in their entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2032 lines

1/3/10 (Item 10 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03028669

Utility
SULFATED DISACCHARIDE INHIBITORS OF SELECTINS, METHODS FOR SYNTHESIS AND THERAPEUTIC USE
[Complexing with selectin]

PATENT NO.: 5,977,080
ISSUED: November 02, 1999 (19991102)
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Bertozzi, Carolyn, Berkeley, CA (California), US (United States of America)
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 9-4,598
FILED: January 08, 1998 (19980108)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 08-518,381 filed Aug. 23, 1995 and now issued as U.S. Pat. No. 5,783,693, the disclosure of which is herein incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made in part with Government support under grant number GM-23547 awarded by the National Institute of Health. The Government may have certain rights in this application.

FULL TEXT: 1170 lines

1/3/11 (Item 11 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03023670

Utility

TIE LIGANDS HOMOLOGUES

["TIE" or "tie" are acronyms, which stand for "tyrosine kinase containing Ig and EGF homology domains"; present invention concerns novel human TIE ligand homologues with powerful effects on vasculature; antitumor agents]

PATENT NO.: 5,972,338

ISSUED: October 26, 1999 (19991026)

INVENTOR(s): Godowski, Paul J., Pacifica, CA (California), US (United States of America)
Gurney, Austin L., Belmont, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), So. San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 8-933,821

FILED: September 19, 1997 (19970919)

FULL TEXT: 2964 lines

1/3/12 (Item 12 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03016320

Utility

SYNTHETIC MULTIVALENT SLE.SUP.X CONTAINING POLYLACTOSAMINES AND METHODS FOR USE

[Treating inflammatory responses, blocking lymphocyte for binding to oligosaccharides on the endothelial surface, blocking bacterial adherence to endothelium and preventing bacterial infections, cancer treatment]

PATENT NO.: 5,965,544

ISSUED: October 12, 1999 (19991012)

INVENTOR(s): Renkonen, Ossi, Espoo, FI (Finland)
Renkonen, Risto, Espoo, FI (Finland)

ASSIGNEE(s): Glycim Oy, (A Non-U.S. Company or Corporation), Espoo, FI (Finland)
[Assignee Code(s): 51087]

APPL. NO.: 8-722,573

FILED: September 27, 1996 (19960927)

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to the earlier-filed U.S. Provisional Application Ser. Nos. 60-007,867, filed Dec. 1, 1995, and 60-004,623, filed Sep. 29, 1995.

FULL TEXT: 2420 lines

1/3/13 (Item 13 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03012764

Utility

INHIBITION OF SELECTIN BINDING

[Using crosslinked lipid]

PATENT NO.: 5,962,422

ISSUED: October 05, 1999 (19991005)

INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)

Spevak, Wayne R., Albany, CA (California), US (United States of America)
Dasgupta, Falguni, New Delhi, IN (India)
Bertozzi, Carolyn, Albany, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-807,428
FILED: February 28, 1997 (19970228)
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, pending, which is hereby incorporated herein by reference in its entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2061 lines

1/3/14 (Item 14 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972981

Utility

TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR

[Antiarthritic agents, skin disorders, insulin dependent diabetes, antiulcer agents and wound healing agents]

PATENT NO.: 5,925,349
ISSUED: July 20, 1999 (19990720)
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)
Imai, Yasuyuki, Tokyo, JP (Japan)
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-916,766
FILED: August 19, 1997 (19970819)
CROSS-REFERENCES

"This application is a divisional of U.S. patent application Ser. No. 08-496,857, filed Jun. 30, 1995, now U.S. Pat. No. 5,695,752, which application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned", which is a continuation-in-part of our earlier filed applications Ser. No. 07-943,817 filed Sep. 11, 1992, now abandoned, and Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference in their entirety, and to which applications we claim priority under 35 USC selection 120.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1523 lines

1/3/15 (Item 15 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02956770

Utility

HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

[Monoclonal antibody or antigen binding fragment against tyrosine kinase receptors; diagnosis/treatment of cardiovascular disorders; antitumor/antiinflammatory agents]

PATENT NO.: 5,910,574

ISSUED: June 08, 1999 (19990608)

INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Shelton, David L., Pacifica, CA (California), US (United States of America)
Urfer, Roman, Pacifica, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 8-457,880

FILED: May 31, 1995 (19950531)

This is a continuation of application(s) Ser. No. 08-286,846 filed on Aug. 5, 1994 which is a continuation in part of application Ser. No. 08-215,139, filed Mar. 18, 1994, now abandoned which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC selection 120.

FULL TEXT: 4335 lines

1/3/16 (Item 16 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02918917

Utility

HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

[Nucleic acid coding for chimeric polypeptide with immunoglobulin constant domain fused to neurotrophin binding polypeptide of human tyrosine kinase receptor; for analgesics and treatment of nervous system disorders]

PATENT NO.: 5,877,016

ISSUED: March 02, 1999 (19990302)

INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Shelton, David L., Pacifica, CA (California), US (United States of America)
Urfer, Roman, Pacifica, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 8-286,846

FILED: August 05, 1994 (19940805)

This application is a continuation-in-part of copending application Serial No. 08-215,139 filed 18 Mar. 1994, now abandoned.

FULL TEXT: 4307 lines

1/3/17 (Item 17 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02893126

Utility
USE OF NUCLEIC ACID LIGANDS IN FLOW CYTOMETRY

PATENT NO.: 5,853,984
ISSUED: December 29, 1998 (19981229)
INVENTOR(s): Davis, Ken, Los Altos, CA (California), US (United States of America)
Jayasena, Sumedha, Boulder, CO (Colorado), US (United States of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 8-479,729
FILED: June 07, 1995 (19950607)

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application Ser. No. 07-714,131, filed Jun. 10, 1991, entitled "Nucleic Acid Ligands" now issued as U.S. Pat. No. 5,475,096, which is a Continuation-in-Part of U.S. patent application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled "Systematic Evolution of Ligands by Exponential Enrichment", now abandoned, and U.S. patent application Ser. No. 07-964,624, filed Oct. 21, 1992, entitled Nucleic Acid Ligands to HIV-RT and HIV-1 Rev now issued as U.S. Pat. No. 5,496,930, U.S. patent application Ser. No. 08-199,507, filed Feb. 22, 1994, entitled Methods for Identifying "Nucleic Acid Ligands of Human Neutrophil Elastase" now issued as U.S. Pat. No. 5,472,841 and U.S. patent application Ser. No. 08-234,997, filed Apr. 28, 1994, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX" now issued as U.S. Pat. No. 5,683,867.

FULL TEXT: 1057 lines

1/3/18 (Item 18 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02881960

Utility
HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

PATENT NO.: 5,844,092
ISSUED: December 01, 1998 (19981201)
INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Shelton, David L., Pacifica, CA (California), US (United States of America)
Urfer, Roman, Pacifica, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), S. San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-359,705
FILED: December 20, 1994 (19941220)

This application is a continuation in part of copending application Ser. No. 08-286,846, filed 5 Aug., 1994, which is a continuation-in-part of application Ser. No. 08-215,139 filed 18 Mar., 1994, now abandoned.

FULL TEXT: 4366 lines

1/3/19 (Item 19 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02871377

Utility

USE OF CHIMERIC SELECTINS AS SIMULTANEOUS BLOCKING AGENTS FOR COMPONENT SELECTIN FUNCTION

[Composite of lectin and epidermal growth factor domains, treatment of pathological leukocyte mediated inflammation]

PATENT NO.: 5,834,425

ISSUED: November 10, 1998 (19981110)

INVENTOR(s): Tedder, Thomas F., S. Natick, MA (Massachusetts), US (United States of America)
Kansas, Geoffrey S., Watertown, MA (Massachusetts), US (United States of America)

ASSIGNEE(s): Dana-Farber Cancer Institute, Inc , (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)

[Assignee Code(s): 11804]

APPL. NO.: 8-461,592

FILED: June 05, 1995 (19950605)

RELATED APPLICATIONS

This application is a division of United States application Ser. No. 08-340,539, filed Nov. 16, 1994, which is a continuation of United States application Ser. No. 08-008,459, filed Jan. 25, 1993, now abandoned which is a continuation-in-part of Tedder, U.S. patent application Ser. No. 07-983, 606, filed Nov. 30, 1992, which is a continuation under 37 CFR 1.62 of Ser. No. 07-730,503, filed Jul. 8, 1991, and Ser. No. 07-313,109, filed Feb. 21, 1989, both now abandoned and a continuation-in-part of Tedder, U.S. patent application Ser. No. 07-700,773, filed May 15, 1991 now abandoned; of Tedder, and a CIP of application Ser. No. 07-737,092, filed Jul. 29, 1991 now abandoned; of Tedder et al., U.S. patent application Ser. No. 07-770,608, filed Oct. 3, 1991 now abandoned; and of Tedder et al., U.S. patent application Ser. No. 07-862,483, filed Apr. 2, 1992 now U.S. Pat. No. 5,389,520, the whole of which are hereby incorporated by reference herein.

GOVERNMENT RIGHTS

Part of the work leading to this invention was made with United States Government funds. Therefore, the U.S. Government has certain rights in this invention.

FULL TEXT: 1429 lines

1/3/20 (Item 20 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02857173

Utility

METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES

[Genetic engineering]

PATENT NO.: 5,821,333
ISSUED: October 13, 1998 (19981013)
INVENTOR(s): Carter, Paul J., San Francisco, CA (California), US (United States of America)
Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Ridgway, John B., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Genetech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-434,869
FILED: May 03, 1995 (19950503)

This application is a divisional of co-pending U.S. application Ser. No. 08-399,106 filed 1 Mar. 1995, which application is incorporated herein by reference and to which application priority is claimed under 35 USC 120.

FULL TEXT: 2618 lines

1/3/21 (Item 21 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842967

Utility
CHIMERIC SELECTINS AS SIMULTANEOUS BLOCKING AGENTS FOR COMPONENT SELECTIN FUNCTION
[Polypeptide]

PATENT NO.: 5,808,025
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Tedder, Thomas F., S. Natick, MA (Massachusetts), US (United States of America)
Kansas, Geoffrey S., Watertown, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Dana-Farber Cancer Institute, Inc , (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 11804]
APPL. NO.: 8-340,539
FILED: November 16, 1994 (19941116)

RELATED APPLICATIONS

This application is a continuation of United States application Ser. No. 08-008,459, filed Jan. 25, 1993, now abandoned.

GOVERNMENT RIGHTS

Part of the work leading to this invention was made with United States Government funds. Therefore, the U.S. Government has certain rights in this invention.

FULL TEXT: 1736 lines

1/3/22 (Item 22 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842664

Utility
METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES

[Genetic engineering]

PATENT NO.: 5,807,706
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Carter, Paul J., San Francisco, CA (California), US (United States of America)
Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Ridgway, John B., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc., (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-433,105
FILED: May 03, 1995 (19950503)

CROSS REFERENCES

This application is a divisional of co-pending U.S. application Ser. No. 08-399,106 filed Mar. 1, 1995, which application is incorporated herein by reference and to which application priority is claimed under 35 USC selection 120.

FULL TEXT: 2625 lines

1/3/23 (Item 23 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02816930

Utility
METHODS FOR SYNTHESIZING SULFATED DISACCHARIDE INHIBITORS OF SELECTINS
[Sulfation lactose with sulfur trioxide]

PATENT NO.: 5,783,693
ISSUED: July 21, 1998 (19980721)
INVENTOR(s): Bertozzi, Carolyn, San Francisco, CA (California), US (United States of America)
Rosen, Steven D., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-518,381
FILED: August 23, 1995 (19950823)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application Ser. No. 08-432,849, filed May 2, 1995, now U.S. Pat. No. 5,489,578, which is a continuation of patent application Ser. No. 08-155,947, filed Nov. 10, 1993 (now abandoned), both of which applications are incorporated herein by reference and to which applications we claim priority under 35 USC selection 120.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made in part with Government support under grant number GM-23547 awarded by the National Institute of Health. The Government may have certain rights in this application.

FULL TEXT: 1155 lines

1/3/24 (Item 24 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02813400

Utility
HIGH AFFINITY NUCLEIC ACID LIGANDS TO LECTINS

PATENT NO.: 5,780,228
ISSUED: July 14, 1998 (19980714)
INVENTOR(s): Parma, David H., Boulder, CO (Colorado), US (United States of America)
Hicke, Brian, Boulder, CO (Colorado), US (United States of America)
Bridonneau, Philippe, Boulder, CO (Colorado), US (United States of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 8-479,724
FILED: June 07, 1995 (19950607)

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application Ser. No. 07-714,131, filed Jun. 10, 1991, entitled Nucleic Acid Ligands, now U.S. Pat. No. 5,475,096 which is a Continuation-in Part of U.S. patent application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled Systematic Evolution of Ligands by Exponential Enrichment, now abandoned, and U.S. patent application Ser. No. 07-964,624, filed Oct. 21, 1992, entitled Methods of Producing Nucleic Acid Ligands, now U.S. Pat. No. 5,496,938.

FULL TEXT: 4953 lines

1/3/25 (Item 25 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02803597

Utility
RECEPTOR ACTIVATION WITH INACTIVE HEPATOCYTE GROWTH FACTOR LIGANDS
[Ligand induced oligomerization of cell surface receptors]

PATENT NO.: 5,770,704
ISSUED: June 23, 1998 (19980623)
INVENTOR(s): Godowski, Paul J., Pacifica, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-792,078
FILED: January 31, 1997 (19970131)

This is a continuation of application Ser. No. 08-423,291 filed on 17 Apr., 1995, now abandoned, which is a divisional of Ser. No. 08-268,880 filed 30 Jun., 1994, now abandoned, which is a continuation application of Ser. No. 07-950,572 filed 20 Sep., 1992, now abandoned, which is a continuation-in-part application of Ser. No. 07-884,811 filed 18 May, 1992 (issued as U.S. Pat. No. 5,316,921) and a continuation-in-part application of Ser. No. 07-885,971 filed 18 May, 1992 (issued as U.S. Pat. No. 5,328,837) which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC selection 120.

FULL TEXT: 2525 lines

1/3/26 (Item 26 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799650

Utility
METHOD FOR IDENTIFICATION OF HIGH AFFINITY NUCLEIC ACID LIGANDS TO
SELECTINS
[Complexing]

PATENT NO.: 5,766,853
ISSUED: June 16, 1998 (19980616)
INVENTOR(s): Parma, David H., Boulder, CO (Colorado), US (United States of
America)
Hicke, Brian James, Boulder, CO (Colorado), US (United States
of America)
Gold, Larry, Boulder, CO (Colorado), US (United States of
America)
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation)
, Boulder, CO (Colorado), US (United States of America)
[Assignee Code(s): 37214]
APPL. NO.: 8-472,255
FILED: June 07, 1995 (19950607)

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application
Ser. No. 07-714,131, filed Jun. 10, 1991, entitled Nucleic Acid Ligands now
U.S. Pat. No. 5,475,096, which is a Continuation-in Part of U.S. patent
application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled Systematic
Evolution of Ligands by Exponential Enrichment, now abandoned, and U.S.
patent application Ser. No. 07-964,624, filed Oct. 21, 1992, entitled
Methods of Producing Nucleic Acid Ligands, now U.S. Pat. No. 5,496,938.

FULL TEXT: 4910 lines

1/3/27 (Item 27 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02796232

Utility
RECEPTOR ACTIVATION WITH HEPATOCYTE GROWTH FACTOR AGONISTS

PATENT NO.: 5,763,584
ISSUED: June 09, 1998 (19980609)
INVENTOR(s): Godowski, Paul J., Burlingame, CA (California), US (United
States of America)
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), San
Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-435,764
FILED: May 05, 1995 (19950505)

This is a continuation of application Ser. No. 08-087,784 filed on 13
Jul. 1993, now abandoned, which is a Section 371 application of
PCT-US93-04717 filed on 17 May 1993, which is a continuation-in-part
application of Ser. No. 07-950,572 filed on 21 Sep. 1992, now abandoned,
which is a continuation-in-part application of Ser. No. 07-884,811 filed on
18 May 1992, now U.S. Pat. No. 5,316,421 and Ser. No. 07-885,971 filed on
18 May 1992, now U.S. Pat. No. 5,328,837 which applications are
incorporated herein by reference.

FULL TEXT: 2844 lines

1/3/28 (Item 28 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02761749

Utility

METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES

PATENT NO.: 5,731,168
ISSUED: March 24, 1998 (19980324)
INVENTOR(s): Carter, Paul J., San Francisco, CA (California), US (United States of America)
Presta, Leonard G., San Francisco, CA (California), US (United States of America)
Ridgway, John B., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-399,106
FILED: March 01, 1995 (19950301)
FULL TEXT: 2684 lines

1/3/29 (Item 29 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721611

Utility

TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR

PATENT NO.: 5,695,752
ISSUED: December 09, 1997 (19971209)
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)
Imai, Yasuyuki, Tokyo, JP (Japan)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-496,857
FILED: June 30, 1995 (19950630)

CROSS-REFERENCES

This application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned, which is a continuation-in-part of earlier filed U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, and earlier filed U.S. application Ser. No. 08-155,947, filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference and to which applications we claim priority under 35 U.S.C. selection 120.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1641 lines

1/3/30 (Item 30 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02672916

Utility
METHOD FOR PURIFICATION OF **L-SELECTIN LIGANDS**
[Chromatography]

PATENT NO.: 5,652,343
ISSUED: July 29, 1997 (19970729)
INVENTOR(s): Lasky, Laurence A., Sausalito, CA (California), US (United States of America)
Imai, Yasuyuki, Tokyo, JP (Japan)
Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Singer, Mark S., Berkeley, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
The Regents of the University of California, (A U.S. Company or Corporation), Berkeley, CA (California), US (United States of America)
[Assignee Code(s): 7579; 13234]
APPL. NO.: 8-294,675
FILED: August 23, 1994 (19940823)

This is a continuation of application Ser. No. 08-018,994, filed Feb. 18, 1993, now U.S. Pat. No. 5,484,891, which is a continuation of application Ser. No. 07-834,902, filed Feb. 13, 1993, now U.S. Pat. No. 5,304,640, which is a continuation-in-part of application Ser. No. 07-695,805, filed May 6, 1991, now U.S. Pat. No. 5,318,890.

FULL TEXT: 2267 lines

1/3/31 (Item 31 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02642857

Utility
DERIVATIVES OF TRITERPENOID ACIDS AS INHIBITORS OF CELL-ADHESION MOLECULES ELAM-1 (E-SELECTIN) AND LECAM-1 (L-SELECTIN)
[Endothelial leukocyte cell adhesion to substrates]

PATENT NO.: 5,624,909
ISSUED: April 29, 1997 (19970429)
INVENTOR(s): Rao, Narasinga, Alameda, CA (California), US (United States of America)
Anderson, Mark B., Orinda, CA (California), US (United States of America)
Naleway, John J., Eugene, OR (Oregon), US (United States of America)
Musser, John H., San Carlos, CA (California), US (United States of America)
ASSIGNEE(s): Glycomed Incorporated, (A U.S. Company or Corporation), Alameda, CA (California), US (United States of America)
[Assignee Code(s): 24436]
APPL. NO.: 8-468,888
FILED: June 06, 1995 (19950606)

This is a divisional of application Ser. No. 07-943,356 filed on Sep. 10,

1992 now U.S. Pat. No. 5,519,008.

FULL TEXT: 1584 lines

1/3/32 (Item 32 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02603532

Utility
POLYGLYCOMERS
[Antiinflammatory agents]

PATENT NO.: 5,587,442
ISSUED: December 24, 1996 (19961224)
INVENTOR(s): Kiessling, Laura L., 2320 Lakeland Ave., Madison, WI
(Wisconsin), US (United States of America), 53704
Manning, David D., 1906 Pike Dr., Apt. 1, Madison, WI
(Wisconsin), US (United States of America), 53713
Mortell, Kathleen H., 202 G Eagle Heights, Madison, WI
(Wisconsin), US (United States of America), 53705
[Assignee Code(s): 68000]
EXTRA INFO: Assignment transaction [Reassigned], recorded March 13,
1995 (19950313)
APPL. NO.: 8-363,503
FILED: December 23, 1994 (19941223)

This invention was made with United States government support awarded by NIH Grant #CM49975 and NSF Grant No. CHE-9357093. The United States Government has certain rights in this invention.

FULL TEXT: 1049 lines

1/3/33 (Item 33 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02596329

Utility
SULFATE LIGANDS FOR L-SELECTINS AND METHODS OF PREVENTING SULFATE ADDITION
[Sulfated oligosaccharides as agonists treating inflammation]

PATENT NO.: 5,580,862
ISSUED: December 03, 1996 (19961203)
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United
States of America)
Imai, Yasuyuki, Tokyo, JP (Japan)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company
or Corporation), Oakland, CA (California), US (United States
of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-422,639
FILED: April 14, 1995 (19950414)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, which application is incorporated herein by reference in its entirety and to which application we claim priority under 35 U.S.C. selection 120.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 994 lines

1/3/34 (Item 34 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02528535

Utility
DERIVATIVES OF TRITERPENOID ACIDS AS INHIBITORS OF CELL-ADHESION MOLECULES
ELAM-1 (E-SELECTIN) AND LECAM-1 (L-SELECTIN)
[Antiinflammatory agents]

PATENT NO.: 5,519,008
ISSUED: May 21, 1996 (19960521)
INVENTOR(s): Rao, Narasinga, Alameda, CA (California), US (United States of America)
Anderson, Mark B., Orinda, CA (California), US (United States of America)
Naleway, John J., Eugene, OR (Oregon), US (United States of America)
Musser, John H., San Carlos, CA (California), US (United States of America)
ASSIGNEE(s): Glycomed Incorporated, (A U.S. Company or Corporation),
Alameda, CA (California), US (United States of America)
[Assignee Code(s): 24436]
EXTRA INFO: Expired, effective May 21, 2000 (20000521), recorded in O.G.
of August 1, 2000 (20000801)
APPL. NO.: 7-943,356
FILED: September 10, 1992 (19920910)
FULL TEXT: 1654 lines

1/3/35 (Item 35 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02495999

Utility
SULFATED LIGANDS FOR L-SELECTIN AND METHODS OF TREATING INFLAMMATION
[Antiinflammatory agents]

PATENT NO.: 5,489,578
ISSUED: February 06, 1996 (19960206)
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-432,849
FILED: May 02, 1996 (19960502)

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, which we claim priority under 35 USC section 120 and which is incorporated herein by reference.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1822 lines

1/3/36 (Item 36 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02490766

Utility
SELECTIN LIGANDS
[Pure polypeptide able to hybridize under low stringency conditions;
glycoproteins]

PATENT NO.: 5,484,891
ISSUED: January 16, 1996 (19960116)
INVENTOR(s): Lasky, Laurence A., Sausalito, CA (California), US (United States of America)
Imai, Yasuyuki, Tokyo, JP (Japan)
Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Singer, Mark S., Berkeley, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
The Regents of the University of California, (A U.S. Company or Corporation), Berkeley, CA (California), US (United States of America)
[Assignee Code(s): 7579; 13234]
APPL. NO.: 8-18,994
FILED: February 18, 1993 (19930218)

This is a divisional of application Ser. No. 07-834,902 filed on 13 Feb. 1992, now U.S. Pat. No. 5,304,640 which is a continuation-in-part of U.S. application Ser. No. 07-695,805 filed 6 May 1991. now U.S. Pat. No. 5,318,830.

FULL TEXT: 2220 lines

1/3/37 (Item 37 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02290512

Utility
DNA SEQUENCE ENCODING A SELECTIN LIGAND

PATENT NO.: 5,304,640
ISSUED: April 19, 1994 (19940419)
INVENTOR(s): Lasky, Laurence A., Sausalito, CA (California), US (United States of America)
Imai, Yasuyuki, San Francisco, CA (California), US (United States of America)
Rosen, Steven D., San Francisco, CA (California), US (United States of America)
Singer, Mark S., Berkeley, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), So. San Francisco, CA (California), US (United States of America)
Regents of the University of California, (A U.S. Company or Corporation), Alameda, CA (California), US (United States of America)

[Assignee Code(s): 7579; 13234]
APPL. NO.: 7-834,902
FILED: February 13, 1992 (19920213)

BACKGROUND OF THE INVENTION

This is a continuation-in-part of U.S. application Ser. No. 07-695,805
filed 6 May 1991.

May 1991.

FULL TEXT: 2217 lines
? t sl/kwic/all

1/KWIC/1 (Item 1 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... of a contemplated application of the method, a molecule that forms an E-, P- or **L-selectin ligand** when contacted with C2GnT-M, either alone or in conjunction with additional glycosylases, can be...

1/KWIC/2 (Item 2 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...known, and are disclosed, for example, in U.S. Pat. No. 5,304,640 (for **L-selectin ligands**); U.S. Pat. Nos. 5,

1/KWIC/3 (Item 3 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...known, and are disclosed, for example, in U.S. Pat. Nos. 5,304,640 (for **L-selectin ligands**); 5,316,921 and 5,328,837 (for HGF variants). These chimeras can be made...

1/KWIC/4 (Item 4 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...known, and are disclosed, for example, in U.S. Pat. Nos. 5,304,640 (for **L-selectin ligands**); 5,316,921 and 5,328,837 (for HGF variants). These chimeras can be made...

1/KWIC/5 (Item 5 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin ligands**, GlyCAM-1 and CD34, which were identified and purified using an L-selectin-IgG affinity...

1/KWIC/6 (Item 6 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin ligands**, GlyCAM-1 and CD34, which were identified and purified using an L-selectin-IgG affinity...

1/KWIC/7 (Item 7 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...for random 40N7 2'NH sub 2 RNA (SEQ. ID NO: 64) and the cloned **L-selectin ligand**, F14.12 (SEQ. ID NO: 78), to peripheral blood

lymphocytes (PBMC).

FIG. 4 shows the...
...greater than that of carbohydrate ligands.

EXAMPLE 9

Specificity of RNA Ligands

The affinity of **L-selectin ligands** to ES-Rg, PS-Rg and CD22 beta -Rg were determined by nitrocellulose partitioning. As...greater specificity than carbohydrate ligands.

EXAMPLE 10

Binding of RNA Ligands to PBMCs

Since the **L-selectin ligands** were isolated against purified, immobilized protein, it is essential to demonstrate that they bind L...

1/KWIC/8 (Item 8 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...L-Selectin nucleic acid ligand

SEQ ID NO: 6
5'-Fgcgagtgtagc tgggtacctt ggctactcg cD-3' **L-Selectin**
ligand beacon

SEQ ID NO: 7
5'-cucaacgagc caggaacauc gaggucagca aacgcgag-3' P-Selectin nucleic acid...
were higher than those used in the example shown in FIG. 9. Then 800 nM
L-Selectin-ligand beacon was added, incubated for an
additional 10 min at the same temperature and fluorescence...

1/KWIC/9 (Item 9 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...treating inflammation. The ligands are sulfooligosaccharides based on
the carbohydrate structures present on the natural **L-selectin**
ligand GlyCAM-1.

U.S. Pat. No. 5,486,536 describes the use of sulfatides as...

1/KWIC/10 (Item 10 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...optimal selectin binding in vivo.

GlyCAM-1 is the best characterized among the three known **L-selectin ligands** and, as a secreted component that is present in serum, may function as a signaling...

1/KWIC/11 (Item 11 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...known, and are disclosed, for example, in U.S. Pat. Nos. 5,304,640 (for **L-selectin ligands**); 5,316,921 and 5,328,837 (for HGF variants). These chimeras can be made...

1/KWIC/12 (Item 12 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... leukocytes to the tissue, its inhibition by free oligosaccharides capable of competing with the natural **L-selectin ligands** is an attractive therapeutic option.

Recognizing the importance of controlling abnormal inflammatory conditions, and cognizant... The invention is further directed to oligosaccharides fulfilling several of the features characteristic to the **L-selectin ligands**: specifically, a dodecameric O-glycosidic core 2 type oligosaccharide alditol with a branched poly lactosamine backbone...

... the enzymatic synthesis of oligosaccharide alditols which share several of the features characteristic of the **L-selectin ligands**, and which are capable of acting as potent inhibitors of **L-selectin ligand** binding. In this embodiment, the NeuNaca alpha 2-3Gal beta 1-4(Fuc1-3)GlcNac...

1/KWIC/13 (Item 13 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... treating inflammation. The ligands are sulfooligosaccharides based on the carbohydrate structures present on the natural **L-selectin ligand** GlyCAM-1.

U.S. Pat. No. 5,486,536 describes the use of sulfatides as...

1/KWIC/14 (Item 14 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...their entirety and specifically to disclose oligosaccharide structures which reportedly act as E-selectin and **L-selectin ligands**

The selectins are a family of three cell-cell adhesion proteins that mediate various leukocyte...sequence similarity among the lectin domains of the selectins is likely to be important for **L-selectin ligands** as well.

The earlier studies have largely focused on which oligosaccharide compounds can act as...

... it would be desirable to provide a sulfation inhibitor which prevents the sulfation only of **L-selectin ligands**, such as by using an inhibitor which inhibits sulfation of a specific carbohydrate chain of...that one unit of the enzyme removes 1 micromole/min. of SO sub 4 from **L-selectin ligands** at physiological pH, then one would administer from 1 to 10 units intravenously to a...

... by calculating the amount of chlorate necessary to inhibit sulfation of a given amount of **L-selectin ligands** and estimating the amount of such ligands within the area to be treated, an amount...of methodologies carried out in order to demonstrate the importance of sulfate groups present on **L-selectin ligands** with respect to their interaction and/or binding with L-selectin. These examples are not...
... A method of treating inflammation resulting from the binding of L-selectin to a sulfated **L-selectin ligand**, said method comprising:

administering to a patient a pharmaceutical preparation comprising a therapeutically effective amount...

... A method of treating inflammation resulting from the binding of L-selectin to a sulfated **L-selectin ligand**, said method comprising:

administering to a patient a pharmaceutical preparation comprising a therapeutically effective amount... A method of treating inflammation resulting from the binding of L-selectin to a sulfated **L-selectin ligand**, said method comprising:

administering to a patient a pharmaceutical preparation comprising a therapeutically effective amount...

1/KWIC/15 (Item 15 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin ligands**, GlyCAM-1 and CD34, which were identified and purified using an L-selectin-IgG affinity...

1/KWIC/16 (Item 16 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin ligands**, GlyCAM-1 and CD34, which were identified and purified using an L-selectin-IgG affinity...

1/KWIC/17 (Item 17 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... effective in detecting HNE beads as is fluoresceinated anti-HNE antibody.

In Example 2, an **L-selectin ligand** is used to determine whether L-selectin is on the surface of lymphocytes.

EXAMPLE 1...

1/KWIC/18 (Item 18 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin ligands**, GlyCAM-1 and CD34, which were identified and purified using an L-selectin-IgG affinity...

1/KWIC/19 (Item 19 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...of imaging the sites of inflammation in a patient involves detecting the expression of the **L-selectin ligand** on the inflamed endothelium. The method includes administering to a patient a pharmaceutical composition consisting...

... carrier. Sufficient time is allowed for the labeled polypeptide to localize at the site of **L-selectin ligand** expression, unbound polypeptide is permitted to clear from healthy tissue in the patient, and signal...

1/KWIC/20 (Item 20 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... node high endothelial venules (HEV). This reagent was also used to isolate and characterize the **L-selectin ligand** (Ashkenazi

et al., supra).

If the two arms of the immunoadhesin structure have different specificities...

1/KWIC/21 (Item 21 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...of imaging the sites of inflammation in a patient involves detecting the expression of the **L-selectin ligand** on the inflamed endothelium. The method includes administering to a patient a pharmaceutical composition consisting...

... carrier. Sufficient time is allowed for the labeled polypeptide to localize at the site of **L-selectin ligand** expression, unbound polypeptide is permitted to clear from healthy tissue in the patient, and signal...

1/KWIC/22 (Item 22 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... node high endothelial venules (HEV). This reagent was also used to isolate and characterize the **L-selectin ligand** (Ashkenazi et al., supra).

If the two arms of the immunoadhesin structure have different specificities...

1/KWIC/23 (Item 23 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...optimal selectin binding in vivo.

GlyCAM-1 is the best characterized among the three known **L-selectin ligands** and, as a secreted component that is present in serum, may function as a signaling...

1/KWIC/24 (Item 24 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...for random 40N7 2'NH sub 2 RNA (SEQ. ID NO: 64) and the cloned **L-selectin ligand**, F14.12 (SEQ. ID NO: 78), to peripheral blood lymphocytes (PBMc).

FIG. 4 shows the...
...greater than that of carbohydrate ligands.

EXAMPLE 9

Specificity of RNA Ligands

The affinity of **L-selectin ligands** to ES-Rg, PS-Rg and CD22 beta -Rg were determined by nitrocellulose partitioning. As...greater specificity than carbohydrate ligands.

EXAMPLE 10

Binding of RNA Ligands to PBMcs

Since the **L-selectin ligands** were isolated against purified, immobilized protein, it is essential to demonstrate that they bind L...

1/KWIC/25 (Item 25 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...07/834,902 filed 13 Feb., 1992 U.S. Pat. No. 5,304,6(for **L-selectin ligands**); 07/884,

1/KWIC/26 (Item 26 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...for random 40N7 2'NH sub 2 RNA (SEQ. ID NO: 64) and the cloned **L-selectin ligand**, F14.12 (SEQ. ID NO: 78), to peripheral blood lymphocytes (PBMC).

FIG. 4 shows the...
...greater than that of carbohydrate ligands.

Example 9

Specificity of RNA Ligands

The affinity of **L-selectin ligands** to ES-Rg, PS-Rg and CD22 beta -Rg were determined by nitrocellulose partitioning. As...greater specificity than carbohydrate ligands.

Example 10

Binding of RNA Ligands to PBMCs

Since the **L-selectin ligands** were isolated against purified, immobilized protein, it is essential to demonstrate that they bind L...

1/KWIC/27 (Item 27 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...07/834,902 filed 13 Feb. 1992, U.S. Pat. No. 5,304,640 (for **L-selectin ligands**); 07/884,811, U.S. Pat. No. 5,316,921 and 07/885,971, U...

1/KWIC/28 (Item 28 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...node high endothelial venules (HEV). This reagent was also used to isolate and characterize the **L-selectin ligand** (Ashkenazi et al., supra).

If the two arms of the immunoadhesin structure have different specificities...

1/KWIC/29 (Item 29 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...their entirety and specifically to disclose oligosaccharide structures which reportedly act as E-selectin and **L-selectin ligands**

The selectins are a family of three cell-cell adhesion proteins that mediate various leukocyte...sequence similarity among the lectin domains of the selectins is likely to be important for **L-selectin ligands** as well.

The earlier studies have largely focused on which oligosaccharide compounds can act as...

... it would be desirable to provide a sulfation inhibitor which prevents the sulfation only of **L-selectin ligands**, such as by using an inhibitor which inhibits sulfation of a specific carbohydrate chain of...that one unit of the enzyme removes 1 micromole/min. of SO₄ from **L-selectin ligands** at physiological pH, then one would administer from 1 to 10 units intravenously to a...

... by calculating the amount of chlorate necessary to inhibit sulfation of a given amount of **L-selectin ligands** and estimating the amount of such ligands within the area to be treated, an amount...of methodologies carried out in order to demonstrate the importance of sulfate groups present on **L-selectin ligands** with respect to their interaction and/or binding with L-selectin. These examples are not...
... A method of treating inflammation resulting from the binding of L-selectin to a sulfated **L-selectin ligand**, comprising:
administering to a patient in need thereof a therapeutically effective amount of a sulfatase...

... sulfatase enzyme to remove a sulfate moiety from a saccharide molecule of a naturally occurring **L-selectin ligand**.

2. The method as claimed in claim 1, wherein the sulfatase enzyme is selected from...

1/KWIC/30 (Item 30 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

METHOD FOR PURIFICATION OF **L-SELECTIN LIGANDS**

... 3A. Illustrates the purification and N-terminal amino acid sequence of the difference 50 kD **L-selectin ligand**. The purification of ligand from conditioned medium was monitored by following added sup 35 S
... 6D. Northern blot analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. FIG. 6A. Total(a) or poly A+ (b, c) RNA was isolated from normal (a...

... 1) kidney and hybridized on Northern blots with (FIG. 6C). the cDNA corresponding to the **L-selectin ligand** or (FIG. 6D). a chicken beta actin cDNA.

FIGS. 7A and 7B. In Situ hybridization analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. Peripheral lymph node sections were hybridized with either an anti-sense (FIG. 7A) or sense (FIG. 7B) hybridization probe corresponding to the **L-selectin ligand** cDNA, washed, exposed to emulsion for 6 weeks and developed. The morphology of the HEV...

... Selectin ligand. Illustrated is one possible model for the structure of the difference 50 kD **L-selectin ligand** on the luminal surface of the peripheral lymph node HEV. The extended brush-like regions
...
...of a selectin ligand.

Another object of the invention is to provide purified selectin, specifically **L-selectin ligands**.

A further object of the present invention is to provide nucleic acid sequences encoding selectin... components. A preliminary biochemical analysis revealed that the difference 50 kD and difference 90 kD **L-selectin ligands** were trypsin-sensitive glycoproteins, containing predominantly O-linked chains. [See co-pending patent ... sequence information has been utilized to clone a cDNA encoding the protein

component of this **L-selectin ligand**. It has been found that the cDNA encodes a novel, highly O-linked (mucin-like...invention concerns an expression vehicle comprising a nucleotide sequence encoding a selectin ligand, preferably an **L-selectin ligand**, operably linked to control sequences recognized by a host cell transformed with the vehicle.

In...

...L-selectin on their surfaces, and can therefore be used in cell adhesion assays for **L-selectin ligands**. Adherent cells can be quantitated by lactate dehydrogenase activity [Bradley et al., J. Cell. Biol... amino acid sequences as compared to the native sequence of a selectin, e.g. an **L-selectin ligand**. Ordinarily, the variants will possess at least 70% homology with a native selectin ligand, and...amino acids 93-122 in FIGS. 4A and 4B (SEQ ID NO:7) of the **L-selectin ligand** amino acid sequence is expected to have more significant effect on the lymphocyte-high endothelial...possess mRNA for the selectin ligand and to express it at a detectable level. An **L-selectin ligand** gene thus may be obtained from a cDNA library prepared from (mesenteric or peripheral) lymph...gene.

An alternative means to isolate the gene encoding a selectin ligand, e.g. an **L-selectin ligand**, is to use polymerase chain reaction (PCR) methodology as described in section 14 of Sambrook...sequences to screen cDNA libraries from various tissues, preferably mammalian lymph node high endothelial venules (**L-selectin ligand**), or myeloid cells (E-selectin and P-selectin ligands). Among the preferred mammals are humans...

... on conserved or highly homologous nucleotide sequences or regions of a selectin ligand, e.g. **L-selectin ligand**.

The DNA shown in FIGS. 4A and 4B (SEQ ID NO:2) may be used to isolate DNA encoding other selectin ligands or to isolate DNA encoding **L-selectin ligand** from another animal species via hybridization employing the methods discussed above. The preferred animals are...the DNA sequence that encodes the protein core of a wild-type selectin, e.g. **L-selectin ligand**. Generally, particular regions or sites of the DNA will be targeted for mutagenesis, and thus...the present invention.

A particularly advantageous purification scheme, specifically developed for the purification of the **L-selectin ligand**, will be described in Example 1. This method takes advantage of a unique selectin receptor selectin receptor to its native ligand. For example, the **L-selectin ligand** effectively blocks the binding of an L-selectin receptor on a circulating leukocyte to its...characterizations of interactions between selectins and their ligands.

EXAMPLE 2

Purification of the 50 kD **L-selectin ligand** for cloning and sequence determination

The work described in Example I demonstrated that the L...

... organ culture (S. Watson-unpublished observations). Thus, the initial step in the purification of the **L-selectin ligand** for sequence determination was to produce large quantities of medium conditioned by murine PLN. A second observation that allowed for a dramatic purification was that difference 50 kD sulfated **L-selectin ligand** was soluble after treatment of conditioned medium with chloroform-methanol. This step resulted in a...with 10 volumes Dulbecco's phosphate-buffered saline (PBS) and the purified material (50 kD **L-selectin ligand**, a.k.a. GlyCAM) was eluted with 10 ml 4 mM EDTA in PBS. This...ID NO:1).

EXAMPLE 4

cDNA Cloning and Sequence Analysis of the .about.50 kD **L-Selectin Ligand**

A murine peripheral lymph node cDNA library was constructed using an InvitroGen cDNA library kit...was found to be difference 14,154 kD. Since the molecular weight of the isolated **L-selectin ligand** is difference 50 kD, this result suggests that difference 70 kD of the glycoprotein mass... prove that the isolated cDNA encodes a sequence corresponding to the protein backbone of an **L-selectin ligand**, we produced peptides derived from the amino acid sequence predicted from the nucleotide sequence of...CAM01, CAM02, CAM05), and each sera was tested for its ability to immunoprecipitate sulfate labeled **L-selectin ligand** that was purified by binding to the L-selectin-IgG chimera as described above.

To...immunoprecipitation. The results are shown in FIGS. 5A and B.

EXAMPLE 6

Expression of the **L-Selectin Ligand**

FIGS. 6A, 6B, 6C and 6D show a Northern blot analysis of the mRNA encoding the difference 50 kD **L-selectin ligand**. As can be seen in FIG. 6A, the mRNA is encoded in the poly A...that we have examined (FIG. 6B).

Analysis of the expression of the mRNA encoding the **L-selectin ligand** in a number of different lymphoid and non-lymphoid tissues reveals that this sequence is...is synthesized by HEV cells, consistent with previous immunohistochemical data demonstrating the localization of the **L-selectin ligand** to this region of the mesenteric and PLN.

The data described here are consistent with...

... Rev. Resp. Dis. 144:S15 (1991)). The high serine and threonine content found in the **L-selectin ligand** described here, coupled with the high degree of glycosylation of the protein (difference 70% by... lectin domain of a selectin. As shown in the model illustrated in FIG. 8, the **L-selectin ligand** may be thought of as a "bottle brush" that extends into the lumen of the...

... the binding avidity of the lymphocyte-HEV adhesive interaction. The mucin-like nature of the **L-selectin ligand** could thus function to present polyvalent carbohydrate ligands to the L-selectin lectin domain via...specific carbohydrate side chains while other O-linked glycoproteins do not. The possibility that the **L-selectin ligand** described here can be ectopically expressed in chronic or acute inflammatory sites to mediate lymphocyte...possible that this domain could function in a similar manner in the case of the **L-selectin ligand**. An alternative hypothesis is that the amphipathic helix could interact weakly with another protein that... glycoprotein versus others as adhesive ligands for L-selectin-mediated trafficking.

The difference 50 kD **L-selectin ligand** is the fourth type of molecule that is involved with cell adhesion in the immune...

... ligands, the immunoglobulin (Ig) superfamily members, 3) the selectins and 4) the difference 50 kD **L-selectin ligand**. The integrins, Ig superfamily members, and selectins have all been found to comprise families containing...

We claim:

1. A method for purification of an **L-selectin ligand** polypeptide, said polypeptide comprising an amino acid sequence encoded by a nucleic acid able to...

...sequence fused to an immunoglobulin heavy chain constant domain sequence with a medium comprising said **L-selectin ligand** polypeptide under conditions in which binding of said chimera to said polypeptide will occur, and...

1/KWIC/31 (Item 31 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...111:2757-2764; Yednock et al., J. Cell Biol. (1987) 104:713-723) suggest the **L-Selectin ligand** may contain fucose, mannose and/or sialic acid, with possible additional anionic components provided by...

1/KWIC/32 (Item 32 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...of multivalency in extracellular interactions.

4. Synthesis of Selectin Ligand

a. Monovalent E-, P- and **L-Selectin Ligands**

Inhibition of selectin requires the attachment of the selectin ligands to various backbones. Consequently, an...

... this glyCAM/position. Disulfate 10 possesses the characteristics of the glyCAM1 determinate of the putative **L-selectin ligand**.

The designs of 8, 9 and 10 are based on the Lewis a rather than...

1/KWIC/33 (Item 33 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... as non-toxic chlorates which metabolically prevent the addition of a sulfate moiety to an **L-selectin ligand** resulting in desirable effects such as alleviation of inflammation.

BACKGROUND OF THE INVENTION

There have... group has been found to play an important role in the attachment of a natural **L-selectin ligand** to its receptor. The metabolic addition of a sulfate to the ligand can be prevented...

... and a sulfate can be removed by the inclusion of a specific sulfatase enzyme. Accordingly, **L-selectin ligand**/receptor binding can be significantly reduced by the administration of a compound which effectively inhibits...

... as a chlorate which metabolically inhibits the addition of a sulfate moiety to a natural **L-selectin ligand**.

Still another object is to provide a method of alleviating inflammation by administering a compound...

... a sulfatase which is an enzyme which specifically removes the sulfate moiety from a natural **L-selectin ligand**.

Yet another object of the present invention is to provide pharmaceutical formulations suitable for inhalation...

... 2) a compound which metabolically inhibits the addition of a sulfate moiety to a natural **L-selectin ligand** and (3) a sulfatase which removes a sulfate from the ligand with (4) a pharmaceutically...

... administering a compound which metabolically inhibits the addition of a sulfate moiety to a natural **L-selectin ligand** and thereby reduces inflammation.

Another advantage of the invention is that inflammatory effects caused by ...

...in the form of a sulfatase which specifically removes the sulfate moiety from a natural **L-selectin ligand**.

Yet another advantage of the invention is that a combined effect on reducing inflammation can...

... 2) a compound which metabolically inhibits the addition of a sulfate moiety to a natural **L-selectin ligand**, and (3) an enzyme which specifically removes a sulfate moiety from a natural ligand.

A...
...12 is SO.sub.3.sup.-.

Secondly, methods of inhibiting the metabolic sulfation of natural **L-selectin ligands** are taught which methods alleviate inflammation as a result of the unsulfated natural ligand's...

... sulfatase enzymes are administered to the patient in order to remove sulfate moieties on natural **L-selectin ligands**.

Fourth, pharmaceutical formulations are taught which contain the sulfated ligands, sulfatases which remove sulfates and...of methodologies carried out in order to demonstrate the importance of sulfate groups present on **L-selectin ligands** with respect to their interaction and/or binding with L-selection receptors. These examples are...

1/KWIC/34 (Item 34 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...111:2757-2764; Yednock et al., J. Cell Biol. (1987) 104:713-723) suggest the **L-Selectin ligand** may contain fucose, mannose and/or sialic acid, with possible additional anionic

1/KWIC/35 (Item 35 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... as non-toxic chlorates which metabolically prevent the addition of a sulfate moiety to an **L-selectin ligand** resulting in desirable effects such as alleviation of inflammation.

BACKGROUND OF THE INVENTION

There have... sequence similarity among the lectin domains of the selectins is likely to be important for **L-selectin ligands** as well.

The earlier studies have largely focused on which oligosaccharide compounds can act as... 2) a compound which metabolically inhibits the addition of a sulfate moiety to a natural **L-selectin ligand**, and (3) an enzyme which specifically removes a sulfate moiety from a natural ligand.

A...

... also includes a method of producing, isolating and identifying the sulfated saccharides within particularly preferred **L-selectin ligands** which are the mild acid hydrolysis products of metabolically radiolabeled GlyCAM-1 isolated by using...of methodologies carried out in order to demonstrate the importance of sulfate groups present on **L-selectin ligands** with respect to their interaction and/or binding with L-selectin receptors. These examples are...

1/KWIC/36 (Item 36 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... 3A. Illustrates the purification and N-terminal amino acid sequence of the difference 50 kD **L-selectin ligand**. The purification of ligand from conditioned medium was monitored by following added sup 35 S ...

... 6. Northern blot analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. A. Total(a) or poly A+ (b, ...and l) kidney and hybridized on Northern blots with C. the cDNA corresponding to the **L-selectin ligand** or D. a chicken beta actin cDNA.

FIG. 7. (Parts A and B) In Situ hybridization analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. Peripheral lymph node sections were hybridized with either an anti-sense (A) or sense (B) hybridization probe corresponding to the **L-selectin ligand** cDNA, washed, exposed to emulsion for 6 weeks and developed. The morphology of the HEV...

... Selectin ligand. Illustrated is one possible model for the structure of the difference 50 kD **L-selectin ligand** on the luminal surface of the peripheral lymph node HEV. The extended brush-like regions ...
...of a selectin ligand.

Another object of the invention is to provide purified selectin, specifically **L-selectin ligands**.

A further object of the present invention is to provide nucleic acid sequences encoding selectin... components. A preliminary biochemical analysis revealed that the difference 50 kD and difference 90 kD **L-selectin ligands** were trypsin-sensitive glycoproteins, containing predominantly O-linked chains. [See co-pending patent application Ser...

... sequence information has been utilized to clone a cDNA encoding the protein component of this **L-selectin ligand**. It has been found that the cDNA encodes a novel, highly O-linked (mucin-like...

... invention concerns an expression vehicle comprising a nucleotide sequence encoding a selectin ligand, preferably an **L-selectin ligand**, operably linked to control sequences recognized by a host cell transformed with the vehicle.

In...

...L-selectin on their surfaces, and can therefore be used in cell adhesion assays for **L-selectin ligands**. Adherent cells can be quantitated by lactate dehydrogenase activity [Bradley et al., J. Cell. Biol... amino acid sequences as compared to the native sequence of a selectin, e.g. an **L-selectin ligand**. Ordinarily, the variants will possess at least 70% homology with a native selectin ligand, and...

...regions (amino acids 42-63 and amino acids 93-122 in FIG. 4) of the **L-selectin ligand** amino acid sequence is expected to ...

possess mRNA for the selectin ligand and to express it at a detectable level. An **L-selectin ligand** gene thus may be obtained from a cDNA library prepared from (mesenteric or peripheral) lymph...

...gene.

An alternative means to isolate the gene encoding a selectin ligand, e.g. an **L-selectin ligand**, is to use polymerase chain reaction (PCR) methodology as described in section 14 of Sambrook...

... sequences to screen cDNA libraries from various tissues, preferably mammalian lymph node high endothelial venules (**L-selectin ligand**), or myeloid cells (E-selectin and P-selectin ligands). Among the preferred mammals are humans regions of a selectin ligand, e.g. **L-selectin ligand**.

The DNA shown in FIG. 4 (SEQ. ID. No.:2) may be used to isolate DNA encoding other selectin ligands or to isolate DNA encoding **L-selectin ligand** from another animal species via hybridization employing the methods discussed above. The preferred animals are...

... the DNA sequence that encodes the protein core of a wild-type selectin, e.g. **L-selectin ligand**. Generally, particular regions or sites of the DNA will be targeted for mutagenesis, and thus...the present invention.

A particularly advantageous purification scheme, specifically developed for the purification of the **L-selectin ligand**, will be described in Example 1. This method takes advantage of a unique selectin receptor...

... block the binding of a corresponding selectin receptor to its native ligand. For example, the **L-selectin ligand** effectively blocks the binding of an L-selectin receptor on a circulating leukocyte to its... characterizations of interactions between selectins and their ligands.

EXAMPLE 2

Purification of the 50 kD **L-selectin ligand** for cloning and sequence determination

The work described in Example 1 demonstrated that the L...

... organ culture (S. Watson-unpublished observations). Thus, the initial step in the purification of the **L-selectin ligand** for sequence determination was to produce large quantities of medium conditioned by murine PLN. A second observation that allowed for a dramatic purification was that difference 50 kD sulfated **L-selectin ligand** was soluble after treatment of conditioned medium with chloroform-methanol. This step resulted in a...with 10 volumes Dulbecco's phosphate-buffered saline (PBS) and the purified material (50 kD **L-selectin ligand**, a.k.a. GlyCAM) was eluted with 10 ml 4 mM EDTA in PBS. This...

...ID. No.:1)).

EXAMPLE 4

cDNA Cloning and Sequence Analysis of the .about.50 kD **L-Selectin Ligand**

A murine peripheral lymph node cDNA library was constructed using an InvitroGen cDNA library kit...was found to be difference 14,154 kD. Since the molecular weight of the isolated **L-selectin ligand** is difference 50 kD, this result suggests that difference 70 kD of the

glycoprotein mass...

... prove that the isolated cDNA encodes a sequence corresponding to the protein backbone of an **L-selectin ligand**, we ...CAM01, CAM02, CAM05), and each sera was tested for its ability to immunoprecipitate sulfate labeled **L-selectin ligand** that was purified by binding to the L-selectin-IgG chimera as described above.

To...

...immunoprecipitation. The results are shown in FIGS. 5A and B.

EXAMPLE 6

Expression of the **L-Selectin Ligand**

FIG. 6 shows a Northern blot analysis of the mRNA encoding the difference 50 kD **L-selectin ligand**. As can be seen in FIG. 6A, the mRNA is encoded in the poly A...that we have examined (FIG. 6B).

Analysis of the expression of the mRNA encoding the **L-selectin ligand** in a number of different lymphoid and non-lymphoid tissues reveals that this sequence is...

... is synthesized by HEV cells, consistent with previous immunohistochemical data demonstrating the localization of the **L-selectin ligand** to this region of the mesenteric and PLN.

The data described here are consistent with...

... Rev. Resp. Dis. 144:S15 (1991)). The high serine and threonine content found in the **L-selectin ligand** described here, coupled with the high degree of glycosylation of the protein (difference 70% by... lectin domain of a selectin. As shown in the model illustrated in FIG. 6, the **L-selectin ligand** may be thought of as a "bottle brush" that extends into the lumen of the...

... the binding avidity of the lymphocyte-HEV adhesive interaction. The mucin-like nature of the **L-selectin ligand** could thus function to present polyvalent carbohydrate ligands to the L-selectin lectin domain via glycoproteins do not. The possibility that the **L-selectin ligand** described here can be ectopically expressed in chronic or acute inflammatory sites to mediate lymphocyte...

...possible that this domain could function in a similar manner in the case of the **L-selectin ligand**. An alternative hypothesis is that the amphipathic helix could interact weakly with another protein that ...

... glycoprotein versus others as adhesive ligands for L-selectin-mediated trafficking.

The difference 50 kD **L-selectin ligand** is the fourth type of molecule that is involved with cell adhesion in the immune...

... ligands, the immunoglobulin (Ig) superfamily members, 3) the selectins and 4) the difference 50 kD **L-selectin ligand**. The integrins, Ig superfamily members, and selectins have all been found to comprise families containing...
...sheared salmon sperm DNA.

4. The polypeptide of claim 1 which is an isolated native **L-selectin ligand**.

5. The polypeptide of claim 1 fused at its C-terminus to the N-terminus ...

... 3A. Illustrates the purification and N-terminal amino acid sequence of the difference 50 kD **L-selectin ligand**. The purification of ligand from conditioned medium was monitored by following added sup 35 S ...

... D). Northern blot analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. A. Total(a) or poly A+ (b, c) RNA was isolated from normal (a,b...and l) kidney and hybridized on Northern blots with C. the cDNA corresponding to the **L-selectin ligand** or D. a chicken beta actin cDNA.

FIG. 7 (Parts N and B). In Situ hybridization analysis of the expression of the mRNA encoding the difference 50 kD **L-selectin ligand**. Peripheral lymph node sections were hybridized with either an anti-sense (A) or sense (B) hybridization probe corresponding to the **L-selectin ligand** cDNA, washed, exposed to emulsion for 6 weeks and developed. The morphology of the HEV...

... Selectin ligand. Illustrated is one possible model for the structure of the difference 50 kD **L-selectin ligand** on the luminal surface of the peripheral lymph node HEV. The extended brush-like regions ...
...of a selectin ligand.

Another object of the invention is to provide purified selectin, specifically **L-selectin ligands**.

A further object of the present invention is to provide nucleic acid sequences encoding selectin... sequence information has been utilized to clone a cDNA encoding the protein component of this **L-selectin ligand**. It has been found that the cDNA encodes a novel, highly O-linked (mucin-like...

... invention concerns an expression vehicle comprising a nucleotide sequence encoding a selectin ligand, preferably an **L-selectin ligand**, operably linked to control sequences recognized by a host cell transformed with the vehicle.

In...
...L-selectin on their surfaces, and can therefore be used in cell adhesion assays for **L-selectin ligands**. Adherent cells can be quantitated by lactate dehydrogenase activity [Bradley et al., J. Cell. Biol... amino acid sequences as compared to the native sequence of a selectin, e.g. an **L-selectin ligand**. Ordinarily, the variants will possess at least 70% homology with a native selectin ligand, and...

...regions (amino acids 42-63 and amino acids 93-122 in FIG. 4) of the **L-selectin ligand** amino acid sequence is expected to have more significant effect on the lymphocyte-high endothelial...possess mRNA for the selectin ligand and to express it at a detectable level. An **L-selectin ligand** gene thus may be obtained from a cDNA library prepared from (mesenteric or peripheral) lymph...

...gene.

An alternative means to isolate the gene encoding a selectin ligand, e.g. an **L-selectin ligand**, is to use polymerase chain reaction (PCR) methodology as described in section 14 of Sambrook...

... sequences to screen cDNA libraries from various tissues, preferably mammalian lymph node high endothelial venules (**L-selectin**

ligand), or myeloid cells (E-selectin and P-selectin ligands). Among the preferred mammals are humans...

... on conserved or highly homologous nucleotide sequences or regions of a selectin ligand, e.g. **L-selectin ligand**.

The DNA shown in FIG. 4 may be used to isolate DNA encoding other selectin ligands or to isolate DNA encoding **L-selectin ligand** from another animal species via hybridization employing the methods discussed above. The preferred animals are...

... the DNA sequence that encodes the protein core of a wild-type selectin, e.g. **L-selectin ligand**. Generally, particular regions or sites of the DNA will be targeted for mutagenesis, and thus...the present invention.

A particularly advantageous purification scheme, specifically developed for the purification of the **L-selectin ligand**, will be described in Example 1. This method takes advantage of a unique selectin receptor...

... block the binding of a corresponding selectin receptor to its native ligand. For example, the **L-selectin ligand** effectively blocks the binding of an L-selectin receptor on a circulating leukocyte to its... characterizations of interactions between selectins and their ligands.

Example 2

Purification of the 50 kD **L-selectin Ligand** for Cloning and Sequence Determination

The work described in Example 1 demonstrated that the L...

... organ culture (S. Watson-unpublished observations). Thus, the initial step in the purification of the **L-selectin ligand** for sequence determination was to produce large quantities of medium conditioned by murine PLN. A second observation that allowed for a dramatic purification was that difference 50 kD sulfated **L-selectin ligand** was soluble after treatment of conditioned medium with chloroform-methanol. This step resulted in a...with 10 volumes Dulbecco's phosphate-buffered saline (PBS) and the purified material (50 kD **L-selectin ligand**, a.k.a. GlyCAM) was eluted with 10 ml 4 mM EDTA in PBS. This...

...level (FIG. 3B).

Example 4

cDNA Cloning and Sequence Analysis of the .about.50 kD **L-Selectin Ligand**

A murine peripheral lymph node cDNA library was constructed using an InvitroGen cDNA library kit...was found to be difference 14,154 kD. Since the molecular weight of the isolated **L-selectin ligand** is difference 50 kD, this result suggests that difference 70 kD of the glycoprotein mass...

... prove that the isolated cDNA encodes a sequence corresponding to the protein backbone of an **L-selectin ligand**, we produced peptides derived from the amino acid sequence predicted from the nucleotide sequence of... CAM01, CAM02, CAM05), and each sera was tested for its ability to immunoprecipitate sulfate labeled **L-selectin ligand** that was purified by binding to the L-selectin-IgG chimera as described above.

To...

...immunoprecipitation. The results are shown in FIGS. 5A and B.

Example 6

Expression of the **L-Selectin Ligand**

FIG. 6 shows a Northern blot analysis of the mRNA encoding the difference 50 kD **L-selectin ligand**. As can be seen in FIG. 6A, the mRNA is encoded in the poly A...that we have examined (FIG. 6B).

Analysis of the expression of the mRNA encoding the **L-selectin ligand** in a number of different lymphoid and non-lymphoid tissues reveals that this sequence is...

... is synthesized by HEV cells, consistent with previous immunohistochemical data demonstrating the localization of the **L-selectin ligand** to this region of the mesenteric and PLN.

The data described here are consistent with...
... Rev. Resp. Dis. 144:S15 (1991)). The high serine and threonine content found in the **L-selectin ligand** described here, coupled with the high degree of glycosylation of the protein (difference 70% by... lectin domain of a selectin. As shown in the model illustrated in FIG. 6, the **L-selectin ligand** may be thought of as a "bottle brush" that extends into the lumen of the...

... the binding avidity of the lymphocyte-HEV adhesive interaction. The mucin-like nature of the **L-selectin ligand** could thus function to present polyvalent carbohydrate ligands to the L-selectin lectin domain via...

... specific carbohydrate side chains while other O-linked glycoproteins do not. The possibility that the **L-selectin ligand** described here can be ectopically expressed in ...possible that this domain could function in a similar manner in the case of the **L-selectin ligand**. An alternative hypothesis is that the amphipathic helix could interact weakly with another protein that...

... glycoprotein versus others as adhesive ligands for L-selectin-mediated trafficking.

The difference 50 kD **L-selectin ligand** is the fourth type of molecule that is involved with cell adhesion in the immune...

... ligands, the immunoglobulin (Ig) superfamily members, 3) the selectins and 4) the difference 50 kD **L-selectin ligand**. The integrins, Ig superfamily members, and selectins have all been found to comprise families containing...
...4.

7. The nucleic acid molecule of claim 1 comprising a nucleotide sequence encoding a **L-selectin ligand**.

8. The nucleic acid molecule of claim 7 wherein said **L-selectin ligand** is murine.

9. The nucleic acid molecule of claim 8 comprising the coding region of
...

5:Biosis Previews(R) 1969-2000/Nov W1
 (c) 2000 BIOSIS
 File 73:EMBASE 1974-2000/Oct W1
 (c) 2000 Elsevier Science B.V.
 *File 73: Update codes are currently undergoing readjustment.
 For details type Help News73.
 File 155:MEDLINE(R) 1966-2000/Dec W4
 (c) format only 2000 Dialog Corporation
 *File 155: For changes to the file and check tags information
 please see Help News155.
 File 399:CA SEARCH(R) 1967-2000/UD=13318
 (c) 2000 American Chemical Society
 *File 399: Use is subject to the terms of your user/customer agreement.
 RANK charge added; see HELP RATES 399.
 File 357:Derwent Biotechnology Abs 1982-2000/Nov B2
 (c) 2000 Derwent Publ Ltd

Set Items Description

 ? e au=sackstein robert ?

Ref	Items	Index-term
E1	2	AU=SACKSTEIN RD
E2	51	AU=SACKSTEIN ROBERT
E3	0	*AU=SACKSTEIN ROBERT ?
E4	1	AU=SACKSTEIN ROBERT D
E5	3	AU=SACKSTEIN, R.
E6	14	AU=SACKSTEIN, ROBERT
E7	2	AU=SACKSTEM R
E8	78	AU=SACKSTON W E
E9	9	AU=SACKSTON, W. E.
E10	1	AU=SACKTON B
E11	378	AU=SACKTOR B
E12	122	AU=SACKTOR B.

Enter P or PAGE for more
 ? s e1-e6

	2	AU=SACKSTEIN RD
	51	AU=SACKSTEIN ROBERT
	0	AU=SACKSTEIN ROBERT ?
	1	AU=SACKSTEIN ROBERT D
	3	AU=SACKSTEIN, R.
	14	AU=SACKSTEIN, ROBERT
S1	71	E1-E6

? s s1 and l(W)selectin(w)ligand

	71	S1
1598360	L	
21511	SELECTIN	
265380	LIGAND	
240	L(W)SELECTIN(W)LIGAND	
S2	7	S1 AND L(W)SELECTIN(W)LIGAND

? rd s2

...completed examining records
 S3 4 RD S2 (unique items)
 ? t s3/7/all

3/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

10891679 BIOSIS NO.: 199799512824

A hematopoietic cell **L-selectin ligand** exhibits
sulfate-independent binding activity.

AUTHOR: **Sackstein Robert**(a); Fu Ling; Allen Katrina L

AUTHOR ADDRESS: (a)Div. Bone Marrow Transplantation, H. Lee Moffitt Cancer
Center Research Inst., 12902 Magnolia Dr**USA

JOURNAL: Blood 89 (8):p2773-2781 1997

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: L-selectin is a leukocyte cell-surface glycoprotein that mediates adhesive interactions between circulating cells and vascular endothelium. All endothelial ligands of L-selectin characterized to date are glycoproteins that require sulfation for activity and share reactivity with MECA 79, a monoclonal antibody that recognizes a sulfate-dependent epitope involved in L-selectin attachment. We have recently identified by functional assay a glycoprotein **L-selectin ligand** expressed on the human hematopoietic cell line KG1a. We report here that this ligand is not recognized by MECA 79 and that it retains binding activity after metabolic inhibition of sulfation by chlorate. A native membrane **L-selectin ligand** exhibiting sulfate-independent function has not been described previously. Identification of this novel ligand on a nonendothelial cell type suggests that structural determinants conferring L-selectin binding may vary in a cell- and tissue-specific manner.

3/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

10738764 BIOSIS NO.: 199799359909

Expression of an **L-selectin ligand** on hematopoietic
progenitor cells.

AUTHOR: **Sackstein Robert**

AUTHOR ADDRESS: Div. Bone Marrow Transplantation, H. Lee Moffitt Cancer
Cent., Res. Inst., 12902 Magnolia Drive, Tam**USA

JOURNAL: Acta Haematologica (Basel) 97 (1-2):p22-28 1997

ISSN: 0001-5792

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The process of hematopoiesis is dependent on discrete cell-cell and cell-matrix interactions which are tightly regulated by expression of adhesion molecules. The process of hematopoiesis is dependent on discrete cell-cell and cell-matrix L-selectin, an adhesion protein best known for regulating leukocyte attachment to endothelium, is characteristically expressed on the earliest hematopoietic progenitor cells. Ligands for L-selectin have been extensively characterized on endothelial cells. We recently identified a ligand for L-selectin expressed on the human hematopoietic progenitor cell line KG1a. This molecule is an integral membrane glycoprotein which is structurally different from all ligands previously described. We hypothesize that this molecule may mediate L-selectin-specific adhesive interactions during hematopoiesis. This article discusses the biology of L-selectin and its ligands, and reviews our current understanding of the structure and distribution of the **L-selectin ligand** expressed on hematopoietic cells.

3/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09589849 BIOSIS NO.: 199598044767
Detection of an **L-selectin ligand** on a hematopoietic progenitor cell line.
AUTHOR: Oxley Susan M; **Sackstein Robert**(a
AUTHOR ADDRESS: (a)Div. Bone Marrow Transplantation, Room 3151, H. Lee Moffitt Cancer Cent., 12902 Magnolia Dr., Ta**USA
JOURNAL: Blood 84 (10):p3299-3306 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: L-selectin, the peripheral lymph node "homing receptor," is an adhesion protein that mediates lymphocyte binding to lymph node high endothelial venules. Ligands for this protein have been identified only on endothelial cells, and recent murine studies indicate that CD34 on endothelial cells is an **L-selectin ligand**. To investigate whether CD34 expressed on hematopoietic cells functions as an **L-selectin ligand**, we used an in vitro binding assay to examine lymphocyte adherence to KG1a, a CD34+ human hematopoietic progenitor cell line. We observed specific L-selectin-mediated adherence of lymphocytes to KG1a: the binding was calcium-dependent, was strictly inhibited by anti-L-selectin antibodies and by carbohydrate ligands of L-selectin, and was abrogated by induction of L-selectin shedding from the lymphocyte membrane by treatment with phorbol esters. However, blocking studies using anti-CD34 antibodies, and experiments using KG1a cells sorted for CD34 expression and COS-7 cells transfected with full-length CD34 cDNA indicate that the ligand on KG1a is not CD34; moreover, RPMI 8402, a CD34+ cell line, does not support lymphocyte adherence in the binding assay. Treatment of KG1a with the enzymes neuraminidase, chymotrypsin, and bromelain abrogated lymphocyte binding to the cells, indicating that the ligand is a glycoprotein. These experiments show that CD34 on hematopoietic cells is not an **L-selectin ligand** and provide the first evidence of a ligand for L-selectin present on a nonendothelial cell.

3/7/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

125056230 CA: 125(5)56230s PATENT
Hematopoietic cell L-selectin ligand (HLL) and therapeutics thereof
INVENTOR(AUTHOR): Sackstein, Robert
LOCATION: USA
ASSIGNEE: University of South Florida
PATENT: PCT International ; WO 9611012 A1 DATE: 960418
APPLICATION: WO 95US13736 (951010) *US 321400 (941011)
PAGES: 60 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-035/12A; A61K-035/14B; A61K-035/28B; A61K-039/395B; A61K-039/44B; C07K-014/435B; C07K-014/705B; C07K-016/18B; C07K-016/28B DESIGNATED COUNTRIES: CA; JP; MX
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA215003 Immunochemistry
CA209XXX Biochemical Methods
IDENTIFIERS: L selectin ligand glycoprotein antibody
DESCRIPTORS:
Ricins...
A chain; clin. uses of immunotoxins that are specific for glycoprotein ligands of L-selectin
Neoplasm...

clin. uses of antibodies to glycoprotein ligands for L-selectin that
 are present on hematopoietic and human tumor cells
 Antibodies... Antibodies,monoclonal... Glycoproteins,biological studies...
 Glycoproteins,specific or class, L-selectins... Hematopoietic precursor
 cell... Immunoassay,immunocytochem.... Leukemia... Neoplasm inhibitors...
 Neoplasm inhibitors,leukemia...
 clin. uses of antibodies to glycoprotein ligands for L-selectin that
 are present on hematopoietic and tumor cells
 Hematopoiesis...
 clin. uses of antibodies to glycoprotein ligands for L-selectin that
 are present on hematopoietic and tumor cells in relation to
 Inflammation...
 clin. uses of antibodies to glycoprotein ligands for L-selectin that
 are present on hematopoietic and tumor cells in relation to
 inflammation treatment
 Animal cell line,KG-1a...
 clin. uses of antibodies to glycoprotein ligands for L-selectin that
 are present on KG1a cells
 Pharmaceutical dosage forms,immunotoxins... Toxins,diphtheria...
 Toxins,exo-, A...
 clin. uses of immunotoxins that are specific for glycoprotein ligands
 of L-selectin
 Staining,biological...
 immunol.; clin. uses of antibodies to glycoprotein ligands for
 L-selectin that are present on hematopoietic and tumor cells
 Adhesion,bio-... Lymphocyte...
 lymphocyte adhesion to hematopoietic cells in relation to a
 glycoprotein ligand for L-selectin
 ? s l(w)selectin(w)ligand?

1598360 L
 21511 SELECTIN
 359858 LIGAND?
 S4 335 L(W)SELECTIN(W)LIGAND?
 ? s s4 and py=1992

335 S4
 1863176 PY=1992
 S5 6 S4 AND PY=1992
 ? rd s5

...completed examining records
 S6 6 RD S5 (unique items)
 ? s s4 and py=1993

335 S4
 1870195 PY=1993
 S7 14 S4 AND PY=1993
 ? rd s7

...completed examining records
 S8 10 RD S7 (unique items)
 ? s s4 and py=1994

335 S4
 1926046 PY=1994
 S9 24 S4 AND PY=1994
 ? rds 9

>>>Unrecognizable Command
 ? rd s9

...completed examining records
 S10 14 RD S9 (unique items)
 ? s s4 and review

335 S4
2495922 REVIEW
S11 15 S4 AND REVIEW
? ?rd s112

>>>Help is not available for RDS112
? rd s11

...completed examining records
S12 14 RD S11 (unique items)
? t s12/3/all

12/3/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

10571461 EMBASE No: 2000036295
Cell adhesion molecules: Selectins and integrins
Gonzalez-Amaro R.; Sanchez-Madrid F.
Dr. F. Sanchez-Madrid, Seccion de Inmunologia, Hospital de la Princesa,
Diego de Leon 62, 28006 Madrid Spain
Critical Reviews in Immunology (CRIT. REV. IMMUNOL.) (United States)
1999, 19/5-6 (389-429)
CODEN: CCRID ISSN: 1040-8401
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 295

12/3/2 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06710274 EMBASE No: 1996375229
Expression of an **L-selectin ligand** on hematopoietic
progenitor cells
Sackstein R.
Division Bone Marrow Transplantation, H.L. Moffitt Cancer Ctr. Res.
Inst., 12902 Magnolia Drive, Tampa, FL 33612-9497 United States
Acta Haematologica (ACTA HAEMATOL.) (Switzerland) 1997, 97/1-2 (22-28)
CODEN: ACHAA ISSN: 0001-5792
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

12/3/3 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06075558 EMBASE No: 1995106037
Cell trafficking and role of adhesion molecules in psoriasis
Smith C.H.; Barker J.N.W.N.
Professorial Unit, St. John's Institute of Dermatology, St. Thomas'
Hospital, Lambeth Palace Road, London SE1 7EH United Kingdom
Clinics in Dermatology (CLIN. DERMATOL.) (United States) 1995, 13/2
(151-160)
CODEN: CLDEE ISSN: 0738-081X
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH

12/3/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

133221300 CA: 133(16)221300q JOURNAL
L-selectin ligand sulfotransferase (LSST)
AUTHOR(S): Hiraoka, Nobuyoshi
LOCATION: The Burnham Institute, USA
JOURNAL: Immunol. Front. DATE: 2000 VOLUME: 10 NUMBER: 4 PAGES:
248-252 CODEN: IMFREG ISSN: 0917-0774 LANGUAGE: Japanese PUBLISHER:
Medikaru Rebyusha

12/3/5 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

132164851 CA: 132(13)164851y JOURNAL
Cloning of a novel HEV-specific sulfotransferase (LSST) required for
L-selectin ligand formation
AUTHOR(S): Miyasaka, Masayuki
LOCATION: Grad. Sch. Med., Osaka Univ., Japan,
JOURNAL: Mol. Med. (Tokyo) DATE: 1999 VOLUME: 36 NUMBER: Rinji
Zokango, Men'eki 1999-2000 PAGES: 236-238 CODEN: MOLMEL ISSN: 0918-6557
LANGUAGE: Japanese PUBLISHER: Nakayama Shoten

12/3/6 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

131017508 CA: 131(2)17508t JOURNAL
Expression of L-selectin ligands in the kidney and their involvement in
leukocyte infiltration
AUTHOR(S): Kawashima, Hiroto; Li, Yong-Fei; Miyasaka, Masayuki
LOCATION: Dep. Bioregulation, Biomedical Res. Center, Osaka Univ. Sch.
Medicine, Suita, Osaka, Japan, 565-0871
JOURNAL: Ensho DATE: 1998 VOLUME: 18 NUMBER: 6 PAGES: 419-424
CODEN: ENSHEE ISSN: 0389-4290 LANGUAGE: Japanese PUBLISHER: Nippon
Ensho Gakkai Jimukyoku

12/3/7 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

129160253 CA: 129(13)160253v JOURNAL
Endothelial sialyl Lewis X as a crucial glycan decoration on L-selectin
ligands
AUTHOR(S): Renkonen, Risto
LOCATION: Department of Bacteriology and Immunology, Haartman Institute,
University of Helsinki, Helsinki, Finland
JOURNAL: Adv. Exp. Med. Biol. DATE: 1998 VOLUME: 435 NUMBER:
Glycoimmunology 2 PAGES: 63-73 CODEN: AEMBAP ISSN: 0065-2598 LANGUAGE:
English PUBLISHER: Plenum Publishing Corp.

12/3/8 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

129160252 CA: 129(13)160252u JOURNAL
Biosynthesis of sulfated L-selectin ligands in human high endothelial
venules (HEV)
AUTHOR(S): Girard, Jean-Philippe; Amalric, Francois
LOCATION: Laboratoire de Biologie Moleculaire Eucaryote du CNRS, 31062,
Toulouse, Fr.
JOURNAL: Adv. Exp. Med. Biol. DATE: 1998 VOLUME: 435 NUMBER:
Glycoimmunology 2 PAGES: 55-62 CODEN: AEMBAP ISSN: 0065-2598 LANGUAGE:
English PUBLISHER: Plenum Publishing Corp.

12/3/9 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

127016289 CA: 127(2)16289c JOURNAL
Glycoprotein ligands for L-selectin
AUTHOR(S): Watson, Susan R.
LOCATION: Nexstar Pharmaceuticals, Boulder, CO, 80301, USA
JOURNAL: Adv. Vasc. Biol. DATE: 1997 VOLUME: 3 NUMBER: Selectins:
Initiators of Leukocyte Endothelial Adhesion PAGES: 179-193 CODEN: AVBIFD
ISSN: 1072-0618 LANGUAGE: English PUBLISHER: Harwood

12/3/10 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

127016288 CA: 127(2)16288b JOURNAL
The carbohydrate components of selectin ligands
AUTHOR(S): Lowe, John B.
LOCATION: Department of Pathology, University of Michigan Medical School,
MSRBI, Ann Arbor, MI, 48109-0650, USA
JOURNAL: Adv. Vasc. Biol. DATE: 1997 VOLUME: 3 NUMBER: Selectins:
Initiators of Leukocyte Endothelial Adhesion PAGES: 143-177 CODEN: AVBIFD
ISSN: 1072-0618 LANGUAGE: English PUBLISHER: Harwood

12/3/11 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

121274482 CA: 121(23)274482j JOURNAL
L-selectin and the ligand molecules
AUTHOR(S): Imai, Yasuyuki
LOCATION: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, Japan, 113
JOURNAL: Immunol. Front. DATE: 1994 VOLUME: 4 NUMBER: 1 PAGES: 25-31
CODEN: IMFREG ISSN: 0917-0774 LANGUAGE: Japanese

12/3/12 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

121006663 CA: 121(1)6663g JOURNAL
Ligands for L-selectin: Where and how many?
AUTHOR(S): Rosen, S. D.
LOCATION: Dep. Anat. and Program Immunol., Univ. Calif., San Francisco,
CA, 94143-0452, USA
JOURNAL: Res. Immunol. DATE: 1993 VOLUME: 144 NUMBER: 9 PAGES:
699-703 CODEN: RIMME5 ISSN: 0923-2494 LANGUAGE: English

12/3/13 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

119243644 CA: 119(23)243644t JOURNAL
Robert Feulgen Lecture 1993. L-selectin and its biological ligands
AUTHOR(S): Rosen, Steven D.
LOCATION: Dep. Anat., Univ. California, San Francisco, CA, 94143-0452,
USA
JOURNAL: Histochemistry DATE: 1993 VOLUME: 100 NUMBER: 3 PAGES:
185-91 CODEN: HCMYAL ISSN: 0301-5564 LANGUAGE: English

12/3/14 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118020476 CA: 118(3)20476t JOURNAL
Marked by a mucin
AUTHOR(S): Seed, Brian
LOCATION: Dep. Mol. Biol., Massachusetts Gen. Hosp., Boston, MA, 02114,
USA
JOURNAL: Curr. Biol. DATE: 1992 VOLUME: 2 NUMBER: 9 PAGES: 457-9
CODEN: CUBLE2 ISSN: 0960-9822 LANGUAGE: English
? ds

Set	Items	Description
S1	71	E1-E6
S2	7	S1 AND L(W)SELECTIN(W)LIGAND
S3	4	RD S2 (unique items)
S4	335	L(W)SELECTIN(W)LIGAND?
S5	6	S4 AND PY=1992
S6	6	RD S5 (unique items)
S7	14	S4 AND PY=1993
S8	10	RD S7 (unique items)
S9	24	S4 AND PY=1994
S10	14	RD S9 (unique items)
S11	15	S4 AND REVIEW
S12	14	RD S11 (unique items)

? t s10/3/all

10/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09711826 BIOSIS NO.: 199598166744
Total synthesis of 3'-O-sialyl, 6'-O-sulfo Lewis-x, NeuAc-alpha-2 fwdarw
3(6-O-SO-3Na)Gal-beta-1 fwdarw 4(Fuc-alpha-1 fwdarw 3)-GlcNAc-beta-OMe: A
major capping group of GLYCAM-I.
AUTHOR: Jain Rakesh K; Vig Rakesh; Rampal Rajit; Chandrasekaran E V; Matta
Khushi L(a)
AUTHOR ADDRESS: (a)Dep. Gynecol. Oncol., Roswell Park Cancer Inst., Elm and
Carlton St., Buffalo, NY 14263**USA
JOURNAL: Journal of the American Chemical Society 116 (26):p12123-12124
1994
ISSN: 0002-7863
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: English

10/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09618670 BIOSIS NO.: 199598073588
Localization of ligands for L-selectin in mouse peripheral lymph node high
endothelial cells by colloidal gold conjugates.
AUTHOR: Kikuta Akio(a); Rosen Steven D
AUTHOR ADDRESS: (a)Dep. Anatomy, Okayama Univ. Med. Sch., 2-5-1
Shikata-cho, Okayama 700**Japan
JOURNAL: Blood 84 (11):p3766-3775 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09615388 BIOSIS NO.: 199598070306
Detection of an **L-selectin ligand** on a human
hematopoietic progenitor cell line.
AUTHOR: Sackstein R; Oxley S
AUTHOR ADDRESS: H. Lee Moffitt Cancer Cent., Univ. South Fla., Tampa, FL**
USA
JOURNAL: Blood 84 (10 SUPPL. 1):p418A 1994
CONFERENCE/MEETING: Abstracts Submitted to the 36th Annual Meeting of the
American Society of Hematology Nashville, Tennessee, USA December 2-6,
1994
ISSN: 0006-4971
RECORD TYPE: Citation
LANGUAGE: English

10/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09606195 BIOSIS NO.: 199598061113
Biological significance of L-selectin (LECAM-1) and its ligand.
BOOK TITLE: International Congress Series; Endothelium-derived factors and
vascular functions
AUTHOR: Miyasaka Masayuki; Tamatani Takuya; Kawashima Hiroto
BOOK AUTHOR/EDITOR: Masaki T: Ed
AUTHOR ADDRESS: Dep. Immunology, Tokyo Metropolitan Inst. Med. Science,
3-18-22 Hon-Komagome, Bunkyo, Tokyo 113**Japan
JOURNAL: International Congress Series (1051):p249-252 1994
BOOK PUBLISHER: Elsevier Science Publishers B.V., PO Box 211, Sara
Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands
Elsevier Science Publishing Co., Inc., P.O. Box 882,
Madison Square Station, New York, New York 10159-2101,
USA
CONFERENCE/MEETING: Fourth International Symposium on Endothelium-Derived
Factors Tokyo, Japan December 7-9, 1993
ISSN: 0531-5131 ISBN: 0-444-81669-0
RECORD TYPE: Citation
LANGUAGE: English

10/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09589849 BIOSIS NO.: 199598044767
Detection of an **L-selectin ligand** on a hematopoietic
progenitor cell line.
AUTHOR: Oxley Susan M; Sackstein Robert(a)
AUTHOR ADDRESS: (a)Div. Bone Marrow Transplantation, Room 3151, H. Lee
Moffitt Cancer Cent., 12902 Magnolia Dr., Ta**USA
JOURNAL: Blood 84 (10):p3299-3306 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

09550900 BIOSIS NO.: 199598005818

Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin.

AUTHOR: Baumhueter Susanne; Dybdal Noel; Kyle Carrie; Lasky Laurence A(a)
AUTHOR ADDRESS: (a)Dep. Immunol., Genetech, Inc., 460 Pt. San Bruno Blvd.,
San Francisco, CA 94080**USA

JOURNAL: Blood 84 (8):p2554-2565 1994

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

10/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

09351347 BIOSIS NO.: 199497359717

Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta-1-integrins, and beta-2-integrins.

AUTHOR: Luscinskas Francis W(a); Kansas Geoffrey S; Ding Han; Pizcueta Pilar; Schleiffenbaum Boris E; Tedder Thomas F; Gimbrone Michael A Jr
AUTHOR ADDRESS: (a)Vascular Res. Div., Dep. Pathol., Brigham and Women's Hosp., 221 Longwood Ave., Boston, MA 02115**USA

JOURNAL: Journal of Cell Biology 125 (6):p1417-1427 1994

ISSN: 0021-9525

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

10/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

09255211 BIOSIS NO.: 199497263581

Alpha-1,3 and alpha-1,3/1,4 fucosyltransferase-dependent synthesis of **L-selectin ligands** sialyl Lewis X and sialyl Lewis a, in cultured endothelial cells.

AUTHOR: Renkonen Risto(a); Majuri Marja-Leena; Niemela Mari Pinola Ritva; Tiisala Sinikka; Natunen Jari; Renkonen Ossi
AUTHOR ADDRESS: (a)Dep. Bacteriol. and Immunol., Inst. Biotechnol., Univ. Helsinki, Helsinki**Finland

JOURNAL: Journal of Cellular Biochemistry Supplement 0 (18D):p267 1994

CONFERENCE/MEETING: Keystone Symposium on Complex Carbohydrates in Biology and Medicine Frisco, Colorado, USA March 19-26, 1994

ISSN: 0733-1959

RECORD TYPE: Citation

LANGUAGE: English

10/3/9 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

05781764 EMBASE No: 1994196394

Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta-1-integrins, and beta-2-integrins

Luscinskas F.W.; Kansas G.S.; Ding H.; Pizcueta P.; Schleiffenbaum B.E.; Tedder T.F.; Gimbrone Jr. M.A.

Vascular Research Division, Department of Pathology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115 United States

Journal of Cell Biology (J. CELL BIOL.) (United States) 1994, 125/6

(1417-1427)
CODEN: JCLBA ISSN: 0021-9525
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

10/3/10 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

121274482 CA: 121(23)274482j JOURNAL
L-selectin and the ligand molecules
AUTHOR(S): Imai, Yasuyuki
LOCATION: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, Japan, 113
JOURNAL: Immunol. Front. DATE: 1994 VOLUME: 4 NUMBER: 1 PAGES: 25-31
CODEN: IMFREG ISSN: 0917-0774 LANGUAGE: Japanese

10/3/11 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

121177632 CA: 121(15)177632a JOURNAL
Myelin localization of a central nervous system ligand for L-selectin
AUTHOR(S): Huang, Kun; Kikuta, Akio; Rosen, Steven D.
LOCATION: Department of Anatomy and Program in Immunology, University of California, San Francisco, CA, 94143-0452, USA
JOURNAL: J. Neuroimmunol. DATE: 1994 VOLUME: 53 NUMBER: 2 PAGES: 133-42
CODEN: JNRIDW ISSN: 0165-5728 LANGUAGE: English

10/3/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

121080907 CA: 121(7)80907f JOURNAL
Infiltrating .gamma..delta. T-cells and selectin endothelial ligands in the cutaneous phytohemagglutinin-induced inflammatory reaction
AUTHOR(S): Whyte, A.; Haskard, D. O.; Binns, R. M.
LOCATION: Dep. Immunol., AFRC Babraham Inst., Cambridge, UK, CB2 4AT
JOURNAL: Vet. Immunol. Immunopathol. DATE: 1994 VOLUME: 41 NUMBER: 1-2
PAGES: 31-40 CODEN: VIIMDS ISSN: 0165-2427 LANGUAGE: English

10/3/13 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

120292388 CA: 120(23)292388s JOURNAL
Identification of the Sulfated Monosaccharides of GlyCAM-1, an Endothelial-Derived Ligand for L-Selectin
AUTHOR(S): Hemmerich, Stefan; Bertozzi, Carolyn R.; Leffler, Hakon; Rosen, Steven D.
LOCATION: Department of Anatomy, University of California, San Francisco, CA, 94143-0452, USA
JOURNAL: Biochemistry DATE: 1994 VOLUME: 33 NUMBER: 16 PAGES: 4820-9
CODEN: BICHAW ISSN: 0006-2960 LANGUAGE: English

10/3/14 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0170788 DBA Accession No.: 94-13339 PATENT
Recombinant glycosylation-dependent cell adhesion molecule production by expression in transgenic rat or transgenic mouse mamma milk - DNA

sequence; **L-selectin ligand** with respiratory and
gastrointestinal pathogen virucide activity for use in infant milk
formulation

PATENT ASSIGNEE: Genentech **1994**

PATENT NUMBER: WO 9418321 PATENT DATE: 940818 WPI ACCESSION NO.:
94-279742 (9434)

PRIORITY APPLIC. NO.: US 13417 APPLIC. DATE: 930201

NATIONAL APPLIC. NO.: WO 94US928 APPLIC. DATE: 940124

LANGUAGE: English

? t s8/3/all

8/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

08885019 BIOSIS NO.: 199396036520

Specific expression of a complex sialyl Lewis X antigen on high endothelial
venules of human lymph nodes: Possible candidate for **L-**
selectin ligand.

AUTHOR: Sawada Mikiko; Takada Akiko; Ohwaki Ichiroh; Takahashi Naofumi;
Tateno Hiroo; Sakamoto Junichi; Kanagi Reiji(a)

AUTHOR ADDRESS: (a)Dep. Experimental Pathol., Research Inst., Aichi Cancer
Center, 1-1 Kanokoden, Chikusaku, Nagoya**Japan

JOURNAL: Biochemical and Biophysical Research Communications 193 (1):p
337-347 1993

ISSN: 0006-291X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/2 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

05703959 EMBASE No: 1994121474

A SV-40 immortalized murine endothelial cell line from peripheral lymph
node high endothelium expresses a new alpha-L-fucose binding protein

Bizouarne N.; Denis V.; Legrand A.; Monsigny M.; Kieda C.

Lab Biochim Glyconjug Lectin Endogen, Ctr Biophysique Moleculaire du
CNRS, Universite d'Orleans, 45071 Orleans Cedex 2 France

Biology of the Cell (BIOL. CELL) (France) 1993, 79/3 (209-218)

CODEN: BCELD ISSN: 0248-4900

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/3 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

05633798 EMBASE No: 1994045633

Endothelial-leukocyte adhesive interactions in inflammatory diseases
Munro J.M.

Department of Histopathology, University College London, Medical School,
University Street, London WC1E 6JJ United Kingdom

European Heart Journal (EUR. HEART J.) (United Kingdom) 1993,
14/SUPPL. K (72-77)

CODEN: EHJOD ISSN: 0195-668X

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/4 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

. (c) 2000 Elsevier Science B.V. All rts. reserv.

05427483 EMBASE No: 1993195582

Cloning of a rat homologue of mouse GlyCAM 1 reveals conservation of structural domains

Dowbenko D.; Watson S.R.; Lasky L.A.

Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
United States

Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 1993
, 268/19 (14399-14403)

CODEN: JBCHA ISSN: 0021-9258

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

8/3/5 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

121006663 CA: 121(1)6663g JOURNAL

Ligands for L-selectin: Where and how many?

AUTHOR(S): Rosen, S. D.

LOCATION: Dep. Anat. and Program Immunol., Univ. Calif., San Francisco,
CA, 94143-0452, USA

JOURNAL: Res. Immunol. DATE: 1993 VOLUME: 144 NUMBER: 9 PAGES:
699-703 CODEN: RIMME5 ISSN: 0923-2494 LANGUAGE: English

8/3/6 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

119243644 CA: 119(23)243644t JOURNAL

Robert Feulgen Lecture 1993. L-selectin and its biological ligands

AUTHOR(S): Rosen, Steven D.

LOCATION: Dep. Anat., Univ. California, San Francisco, CA, 94143-0452,
USA

JOURNAL: Histochemistry DATE: 1993 VOLUME: 100 NUMBER: 3 PAGES:
185-91 CODEN: HCMYAL ISSN: 0301-5564 LANGUAGE: English

8/3/7 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

119219877 CA: 119(21)219877a JOURNAL

Direct demonstration of heterogeneous, sulfated O-linked carbohydrate chains on an endothelial ligand for L-selectin

AUTHOR(S): Imai, Yasuyuki; Rosen, Steven D.

LOCATION: Dep. Anat., Univ. California, San Francisco, CA, 94143-0452,
USA

JOURNAL: Glycoconjugate J. DATE: 1993 VOLUME: 10 NUMBER: 1 PAGES:
34-9 CODEN: GLJOEW ISSN: 0282-0080 LANGUAGE: English

8/3/8 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

119115311 CA: 119(11)115311v JOURNAL

Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells

AUTHOR(S): Norgard-Sumnicht, Karin E.; Varki, Nissi M.; Varki, Ajit

LOCATION: Cancer Cent., Univ. California, San Diego, CA, 92093, USA

JOURNAL: Science (Washington, D. C., 1883-) DATE: 1993 VOLUME: 261
NUMBER: 5120 PAGES: 480-3 CODEN: SCIEAS ISSN: 0036-8075 LANGUAGE:

English

8/3/9 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118206649 CA: 118(21)206649g JOURNAL
Structure and chromosomal localization of the murine gene encoding GLYCAM
1. A mucin-like endothelial ligand for L selectin
AUTHOR(S): Dowbenko, Donald; Andalibi, Ali; Young, Paul E.; Lusic, Aldons
J.; Lasky, Laurence A.
LOCATION: Dep. Immunol., Genentech, Inc., South San Francisco, CA, 94080,
USA
JOURNAL: J. Biol. Chem. DATE: 1993 VOLUME: 268 NUMBER: 6 PAGES:
4525-9 CODEN: JBCHA3 ISSN: 0021-9258 LANGUAGE: English

8/3/10 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118146012 CA: 118(15)146012g JOURNAL
Sulfated glycolipids are ligands for a lymphocyte homing receptor,
L-selectin (LECAM-1), binding epitope in sulfated sugar chain
AUTHOR(S): Suzuki, Yasuo; Toda, Yoshihisa; Tamatani, Takuya; Watanabe,
Toshiki; Suzuki, Takashi; Nakao, Toru; Murase, Katsutoshi; Kiso, Makoto;
Hasegawa, Akira; et al.
LOCATION: Sch. Pharm. Sci., Univ. Shizuoka, Shizuoka, Japan, 422
JOURNAL: Biochem. Biophys. Res. Commun. DATE: 1993 VOLUME: 190
NUMBER: 2 PAGES: 426-34 CODEN: BBRCA9 ISSN: 0006-291X LANGUAGE:
English
? t s6/3/all

6/3/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

05236300 EMBASE No: 1993004385
Substrate specificity of the Trypanosoma cruzi trans-sialidase
Vandekerckhove F.; Schenkman S.; Pontes De Carvalho L.; Tomlinson S.;
Kiso M.; Yoshida M.; Hasegawa A.; Nussenzweig V.
Michael Heidelberger Div of Immunol., Department of Pathology, New York
University Medical Center, 550 First Avenue, New York, NY 10016 United
States
Glycobiology (GLYCOBIOLOGY) (United Kingdom) 1992, 2/6 (541-548)
CODEN: GLYCE ISSN: 0959-6658
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

6/3/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118228470 CA: 118(23)228470u JOURNAL
An endothelial ligand for L-selectin is a novel mucin-like molecule
AUTHOR(S): Lasky, Laurence A.; Singer, Mark S.; Dowbenko, Donald; Imai,
Yasuyuki; Henzel, William J.; Grimley, Chris; Fennie, Christopher; Gillett,
Nancy; Watson, Susan R.; Rosen, Steven D.
LOCATION: Genentech, Inc., South San Francisco, CA, 94080, USA
JOURNAL: Cell (Cambridge, Mass.) DATE: 1992 VOLUME: 69 NUMBER: 6
PAGES: 927-38 CODEN: CELLB5 ISSN: 0092-8674 LANGUAGE: English

6/3/3 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118057634 CA: 118(7)57634u JOURNAL
Further characterization of the interaction between L-selectin and its
endothelial ligands
AUTHOR(S): Imai, Yasuyuki; Lasky, Laurence A.; Rosen, Steven D.
LOCATION: Dep. Anat., Univ. California, San Francisco, CA, 94143-0452,
USA
JOURNAL: Glycobiology DATE: 1992 VOLUME: 2 NUMBER: 4 PAGES: 373-81
CODEN: GLYCE3 LANGUAGE: English

6/3/4 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

118020476 CA: 118(3)20476t JOURNAL
Marked by a mucin
AUTHOR(S): Seed, Brian
LOCATION: Dep. Mol. Biol., Massachusetts Gen. Hosp., Boston, MA, 02114,
USA
JOURNAL: Curr. Biol. DATE: 1992 VOLUME: 2 NUMBER: 9 PAGES: 457-9
CODEN: CUBLE2 ISSN: 0960-9822 LANGUAGE: English

6/3/5 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

117210601 CA: 117(21)210601g JOURNAL
Identification of a soluble form of a ligand for the lymphocyte homing
receptor
AUTHOR(S): Brustein, Marshall; Kraal, Georg; Mebius, Reina E.; Watson,
Susan R.
LOCATION: Dep. Immunol., Genentech, Inc., South San Francisco, CA, 94080,
USA
JOURNAL: J. Exp. Med. DATE: 1992 VOLUME: 176 NUMBER: 5 PAGES: 1415-19
CODEN: JEMEA V ISSN: 0022-1007 LANGUAGE: English

6/3/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0143357 DBA Accession No.: 93-01409 PATENT
Glycoprotein selectin ligand Glycan-1 - may be used as an antiinflammatory;
recombinant ligand expression in 293S cell culture
PATENT ASSIGNEE: Genentech; Univ. Calif. 1992
PATENT NUMBER: WO 9219735 PATENT DATE: 921112 WPI ACCESSION NO.:
92-398862 (9248)
PRIORITY APPLIC. NO.: US 834902 APPLIC. DATE: 920213
NATIONAL APPLIC. NO.: WO 92US3755 APPLIC. DATE: 920506
LANGUAGE: English

Gambel, Phillip

From: Chan, Christina
Sent: Thursday, November 02, 2000 4:25 PM
To: Clemens, Karen; DeCloux, Amy; DiBrino, Marianne; Ewoldt, Gerald; Gambel, Phillip; Huynh, Phuong N.; Nolan, Patrick; Roark, Jessica; Saunders, David; Schwadron, Ronald; Tung, Marybeth; Vandervegt, F. Pierre
Subject: RE: Business Casual Dress

Correction. The following dress code is not for you guys.

-----Original Message-----

From: Chan, Christina
Sent: Thursday, November 02, 2000 3:29 PM
To: Clemens, Karen; Decloux, Amy; DiBrino, Marianne; Ewoldt, Gerald; Gambel, Phillip; Huynh, Phoung; Nolan, Patrick; Roark, Jessica; Saunders, David; Schwadron, Ronald; Tung, Marybeth; Vandervegt, Pierre
Subject: Business Casual Dress

In order to meet the business casual dress code, we do not wear jeans, T-shirts, sweat shirts and/or pants and tennis shoes. Thanks for dressing properly. Chris